University of Wollongong

Research Online
University of Wollongong Thesis Collection
2017+

University of Wollongong Thesis Collections

2021

The mechanism of quinolinic acid-induced neurite lesions: The role of
NR2B, ROS and autophagy
Yuanyi Xie

Follow this and additional works at: https://ro.uow.edu.au/theses1
University of Wollongong
Copyright Warning
You may print or download ONE copy of this document for the purpose of your own research or study. The University
does not authorise you to copy, communicate or otherwise make available electronically to any other person any
copyright material contained on this site.
You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act
1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised,
without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe
their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court
may impose penalties and award damages in relation to offences and infringements relating to copyright material.
Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the
conversion of material into digital or electronic form.
Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily
represent the views of the University of Wollongong.
Research Online is the open access institutional repository for the University of Wollongong. For further information
contact the UOW Library: research-pubs@uow.edu.au

The mechanism of quinolinic acid-induced neurite lesions:
The role of NR2B, ROS and autophagy

Yuanyi Xie

Supervisors:
Professor Xu-Feng Huang
Dr. Yinghua Yu

This thesis is presented as part of the requirement for the conferral of the degree:
DOCTOR OF PHILOSOPHY

University of Wollongong
School of Medicine

Nov. 2021
1

Abstract
Increased quinolinic acid (QA) has been suggested in various mental disease pathology.
Excessive QA is shown to overactivate N-Methyl-D-aspartic acid (NMDA) receptor
subunit 2B (NR2B) receptors and is deleterious to the neurons; however, the exact
mechanism behind this effect is complex and not fully understood. This thesis aimed to
investigate the mechanism of QA-induced neurite impairment.
Increased QA has been known to cause neurite lesions in pathological conditions in an
NMDA receptor-dependent manner. This project investigated the mechanism of how QA
leads to neurite impairment, as in Chapter 2. The results showed that the NR2B
downstream proteins of cAMP response element-binding protein (CREB) and brainderived neurotrophic factor (BDNF) were significantly reduced when treating with
excessive QA. This effect was prevented by NR2B receptor antagonist ifenprodil,
suggesting the involvement of NR2B receptors. Moreover, memantine, which is a partial
antagonist of the NR2B receptor, also reduced the QA-induced neurite lesions.
Furthermore, NR2B siRNA was used to block the NMDA signalling pathway, which also
attenuated the QA-induced neurite lesions in neuronal cells. These results suggest that
excessive QA causes neurite lesions through overactivation of the NR2B receptor and its
downstream proteins CREB and BDNF.
Dopamine D2 receptor (D2R) activation affects NR2B-mediated signalling, which is
relevant to maintaining neurite integrity. Therefore, in Chapter 3, I studied how D2R and
NR2B affect each other in regulating neurite growth. Results showed that both the
overexpression of NR2B and inhibition of D2R caused neurite lesions. In addition, neurite
lesions induced by NR2B overstimulation caused the inhibition of D2R. Conversely, D2R
hypofunction also led to NR2B hyperfunction. Furthermore, using the fluorescence
resonance energy transfer (FRET), I found that the NR2B-D2R interaction was enhanced
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by D2R hyperactivity. In conclusion, this part of the study uncovered that the NR2B
hyperactivity induced D2R hypoactivity, or vice versa, may induce additional effects,
leading to neurite lesions. Therefore, a balanced regulation between D2R and NR2B may
be an important strategy for new drug development to treat severe mental diseases.
Previous studies demonstrated that excessive QA also induced the formation of reactive
oxygen species (ROS). In Chapter 4, I investigated how QA affects ROS and autophagy
in neuronal cells. It was found that excessive QA significantly increased ROS in neuronal
cells. The rising of ubiquitin-binding protein p62 (p62) and Microtubule-associated
proteins 1A/1B light chain 3B (LC3b)-II suggested impairment in the autophagy process.
NR2B antagonist ifenprodil prevented QA-induced ROS production, suggesting the
involvement of NR2B receptors. A low dose of antipsychotic drug olanzapine decreased
ROS, while a high dose of olanzapine showed no effect on excessive QA-induced neurite
lesions. Moreover, low dose olanzapine reduced p62, but not LC3b-II, in SH-SY5Y cells,
suggesting autophagy restored by low dose olanzapine. These results indicate that both
ifenprodil and olanzapine reduce excessive QA-induced ROS formation and impaired
autophagy in neuronal cells.
NR2B hypofunction is a pathology of schizophrenia. The mechanism of action is still
largely unknown, while several hypotheses have been made. In Chapter 5, the
differentially expressed genes between NR2B loss of function (LOF) and control human
cells were identified. The identified genes were used to plot possible protein-protein
interaction networks showing their association strength. Gene Ontology (GO) enrichment
and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to examine
the pathways associated with the differentially expressed genes (DEGs). These results
suggest that the genes associated with neuronal differentiation, ROS, and cell cycle were
significantly changed due to NR2B LOF. These findings offer a systematic approach for
3

a better understanding of the neuropathology of NR2B hypofunction relevant to
schizophrenia.
In conclusion, this project study demonstrated that QA induced neurite lesions via
overstimulation of NR2B receptors and elevated ROS. Thus, the presented findings offer
a new approach to alleviating neurite impairment and oxidative stress in
neurodegenerative diseases with an increased QA.
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Chapter One
1.1

General Introduction

Neurodegenerative diseases are a group of debilitating, incurable, and progressive
neurological diseases. Neurite deficits and cognitive impairment have been shown to
be key features of these diseases, risking human health (Dugger and Dickson 2017).
Therefore, understanding the mechanisms and developing prevention and therapeutic
strategies are crucially important in neurological research. In many neurodegenerative
diseases, such as Alzheimer’s disease (AD) and Huntington's disease, quinolinic acid
(QA) has been found to be abnormally high (Guillemin and Brew 2002, Schwarcz,
Guidetti et al. 2010). Notably, a recent study showed that the plasma QA level was also
abnormal in schizophrenia patients (Cathomas, Guetter et al. 2021). Although it is
already known that QA is a neurotoxin and can overactivate the NMDA receptors
(Braidy, Grant et al. 2009), the exact mechanism is still not clear. Moreover, studies
also showed that excessive QA could increase reactive oxygen species (ROS)
production, which is also an important factor in inducing neurite deficits (Kubicova,
Hadacek et al. 2013). Therefore, excessive QA may be a key factor in
neurodegenerative diseases and schizophrenia. The present series of studies was
designed to elucidate the mechanism of excessive QA effect on neurite deficits and how
memantine and the antipsychotic drug olanzapine reduce QA-induced neurite lesions.
A better comprehension of these mechanisms will help to understand the mechanism of
QA and develop new drugs to treat patients with neurodegenerative diseases or
schizophrenia.
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1.2
1.2.1

Literature Review
Excessive quinolinic acid and severe mental disorders

1.2.1.1 Increased quinolinic acid induced neurite lesions in severe mental
disorders
The neurodegenerative disease includes several incapacitating and incurable conditions
that result from progressive damage to neural cells and connections. They are the main
cause of disability-adjusted life-years (DALYs) and the second cause of death (Gitler,
Dhillon et al. 2017). Neurodegenerative diseases currently affect billions of people
worldwide. Among these diseases, Alzheimer’s disease and Parkinson’s disease are the
most common (Magalingam, Radhakrishnan et al. 2018). While most diseases are
multifactorial, they share some features at the cellular level (Xie, Gao et al. 2014,
Guzman-Martinez, Maccioni et al. 2019, Tan, Karri et al. 2019). For example, cognitive
impairment and memory loss are found in many neurodegenerative diseases (Xu, Yan
et al. 2012). This can be caused by neurite lesions and neuronal death in the brain, which
are affected by many pathogenic factors. For example, amyloid β (Aβ) aggregation and
hyper-phosphorylated tau protein are considered to be important pathogenic factors in
Alzheimer’s disease (Sadigh-Eteghad, Sabermarouf et al. 2015, Kimura, Sharma et al.
2018). While α-synuclein is a well-known cause of Parkinson’s disease (Stefanis 2012).
All these pathogenic proteins can lead to serious neurite lesions and/or cell death both
in vitro and in vivo. QA was observed to be abnormally high in patients with
neurodegenerative diseases (Ting, Brew et al. 2009, Lugo-Huitron, Ugalde Muniz et al.
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2013). In vitro and in vivo studies also showed that excessive QA caused neurite lesions
and neuronal cell death (Perez-De La Cruz, Carrillo-Mora et al. 2012). Therefore, QA
may be a potential target for the treatment of neurodegenerative diseases in the future.
In schizophrenia patients, an increased QA production in the microglia was observed
(Gos, Myint et al. 2014), and the NMDA receptor was shown to be hypofunctional
(Olney, Newcomer et al. 1999, Kristiansen, Huerta et al. 2007). Since QA is an NMDA
receptor agonist, it may contribute to the pathology of schizophrenia. Therefore,
investigating the signalling pathway of QA can help in the detection of the mechanisms
behind schizophrenia.
The concentration of QA in the human brain and cerebrospinal fluid (CSF) in
physiological conditions is low (approximately 100 nM) (Stone 1993). This low
concentration of QA was shown to be important in maintaining the biological functions
of the brain. Stone and his colleague found that the concentration of QA is different
between different brain regions, which suggests that the function of QA might differ
between different regions (Moroni, Lombardi et al. 1984, Stone and Connick 1985).
Notably, QA has its highest concentration in the cortex (2.9 nM/g) (Lombardi, Moneti
et al. 1984). However, many studies on neurodegenerative diseases indicated an
abnormally high concentration of QA. Ting et al. have shown that the concentration of
QA can reach micromolar levels in the brain and CSF in patients with AD (Ting, Brew
et al. 2009). Since QA is a well-known NMDA receptor agonist, excessive QA can lead
to overactivation of the NMDA receptors, resulting in neuronal excitotoxicity (Braidy,
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Grant et al. 2009). Therefore, an excessive QA could contribute to the pathology of
neurodegenerative diseases.
1.2.1.2 Excessive quinolinic acid and neurotoxicity
The kynurenine pathway (KP) is known as the major route for the degradation of
Tryptophan (TRP), which is an essential amino acid (Maddison and Giorgini 2015,
Badawy 2017). In the central nervous system (CNS), TRP is involved in the synthesis
of many metabolic pathways, including the kynurenine and serotonin (Badawy 2017).
The KP produces many essential neuroactive metabolites, including QA, kynurenic
acid (KYNA), and picolinic acid (Maddison and Giorgini 2015). Although all these
compounds are the metabolites of TRP, they have different functions in brain regulation.
For example, while KYNA was proven as an NMDA receptor antagonist (Birch,
Grossman et al. 1988), QA is known to be an NMDA receptor agonist and excitotoxin
in the brain (Braidy, Grant et al. 2009, Guillemin 2012). Many studies have indicated
that excessive QA is related to many psychiatric disorders, such as AD, in which QA is
usually considered the agonist of the NMDA receptors (Ting, Brew et al. 2009). The
QA-induced overactivation of the NMDA receptors results in serious excitotoxicity,
which leads to neurite lesions and neuronal death in the brain (Perez-De La Cruz,
Carrillo-Mora et al. 2012). More details about the neurite lesions induced by the NMDA
receptor hyperactivation will be introduced in 1.2.4. Since QA is the key excitotoxin
compound in the KP, its metabolism might be the most important factor related to the
human pathological processes and is thus worthy of further research.
22

1.2.2

NMDA receptors

1.2.2.1 NMDA receptors and their function
Altered glutamate transmission is thought to contribute to the neuropathology of
psychiatric disorders (Moghaddam and Javitt 2012). NMDA receptors are the main
receptors for the glutamatergic system. In clinical studies, impairments in neurons and
synapses are the main cause of neuropsychiatric diseases, and the NMDA receptor
dysfunction plays an important role in these diseases (Moghaddam and Javitt 2012,
Paoletti, Bellone et al. 2013). In traumatic brain injury and stroke, the glutamate
concentration increases in the CNS, resulting in excitotoxicity, which can lead to rapid
neuronal death (Lai, Shyu et al. 2011). In this case, NMDA receptors are hyperactivated.
Some researchers have suggested this might be due to the activation of extrasynaptic
NMDA receptor signalling pathways (Hardingham and Bading 2010, Gladding and
Raymond 2011). NMDA receptors were overactivated in many neurodegeneration
diseases, such as AD and Parkinson's disease (PD) (Paoletti, Bellone et al. 2013). For
example, in AD, NR2B was found to mediate the harmful effects of Aβ. Therefore,
NR2B antagonists can reduce the Aβ-induced synaptic loss and long-term potentiation
(LTP) impairment (Ronicke, Mikhaylova et al. 2011, Paoletti, Bellone et al. 2013). In
schizophrenia patients, memory loss and cognitive impairment are always observed
together with synaptic plasticity impairment. Rats with NR2B deficits were reported to
show cognitive impairment (Clayton, Mesches et al. 2002), while a better learning
ability was found in aged mice with overexpressed NR2B (Cao, Cui et al. 2007). This
23

suggests that NR2B is crucial for learning and cognition, and the NR2B loss of function
will lead to cognitive impairment. Another study reported that the NMDA receptor
antagonists deteriorate schizophrenia-like symptoms in both healthy people and
patients (Moghaddam and Javitt 2012). Since no significant change was reported in the
expression level of NR2A in aged mice, while the expression of NR2B expression was
decreased (Paoletti, Bellone et al. 2013), NR2B could be more likely related to
schizophrenia in older adults. Furthermore, the antipsychotic drug olanzapine was
shown to improve the NMDA receptor impairment via Fyn Y420 phosphorylation and
NR2B Y1472 phosphorylation (Zhang, Yu et al. 2016). Clozapine was also shown to
have some effects, but its binding site on the NMDAR is still not clear (Bjarnadottir,
Misner et al. 2007, Zhang, Yu et al. 2016). Therefore, QA can cause neurotoxicity by
overactivation of the NMDA receptors and is thus considered an endogenous
neurotoxin in the brain. Understanding the mechanism behind this effect will support
the treatment of neurodegenerative diseases.
NMDAR receptors represent the primary target to regulate cognition and memory
function in the brain. It has already been known that LTP could be produced by the
activation of postsynaptic NMDA receptors in the hippocampus (between CA3 and
CA1) (Bliss and Collingridge 2013). Afterward, NMDA receptors were also found to
be an essential substance in the processes of learning and memory (Rezvani 2006), and
the inhibition of NMDA receptors was reported to lead to cognitive dysfunction and
memory loss (Rowland, Astur et al. 2005). However, the NMDA receptors were found
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to be hyperactivated in patients with neurodegenerative diseases, indicating that the
hyperactivation of the NMDA receptors is detrimental to the neurons (Hynd, Scott et
al. 2004). Therefore, keeping the NMDA receptors in a balanced stimulation is the key
factor to support neuronal connections.
1.2.2.2 NMDA receptors and neurite growth
NMDA receptors are ionotropic glutamate receptors that regulate neuronal
development in the brain. The most important function of these receptors is to allow a
calcium influx upon activation (Hardingham and Bading 2003). Calcium influx was
reported to be able to promote neurite outgrowth and axonal growth cone motility in
neurons (Rusanescu, Qi et al. 1995, Henley and Poo 2004). Moreover, it was shown
that the NMDA receptors are responsible for neuronal migration and synaptic
connectivity in animals (Komuro and Rakic 1993, Hunt and Castillo 2012). Calcium
influx through NMDA receptors also plays a key role in the period of neuron
development. Many studies showed the role of NMDA receptors' mediation of calcium
influx in promoting neuritogenesis in developing neurons (Wang, Petralia et al. 2011).
Schmitz and colleagues reported that in the axonal growth cone, the NMDA receptors
can stimulate axonal growth and splitting (Schmitz, Luccarelli et al. 2009).
1.2.2.3 The binding sites of NR2B
NR2B does not perform its function alone. In fact, about 70 adhesion proteins were
shown to bind to NR2B and regulate its function in the neurons (Grant and O'Dell 2001,
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Fan, Jin et al. 2014). Since NR2B is a glutamate-gated ion channel, and calcium influx
is always considered the main function resulting from NR2B activation, the calciumdependent proteins, such as CaMK II, are thus an important partner in the NR2Bmediated function (Sanz-Clemente, Gray et al. 2013, Fan, Jin et al. 2014). When the
channel is open and calcium influx is increased, it activates the phosphorylation of
CaMK II T286 and translocation of pT286 CaMK II to the dendritic spine (Giese,
Fedorov et al. 1998). After that, CaMK II binds to the 1260-1309 domain in the C
terminal of NR2B (Strack, McNeill et al. 2000, Bayer, De Koninck et al. 2001). In the
work of Strack et al., several point mutations were made in the NR2B 1260-1309 site,
and a specific location (R1300Q and S1303D) double mutation was reported to
eliminate CaMK II binding to NR2B, suggesting that S1303 is the key position for
CaMK II binding (Strack, McNeill et al. 2000). Many studies supported the CaMK IINR2B complex. For instance, Zhou et al. overexpressed the C terminal of NR2B (8391422) and found that the NR2B-CaMK II pathway was blocked (Zhou, Takahashi et al.
2007). Additionally, Matsumura and colleagues found that the phosphorylation of
CaMK II T286 is impaired in NR2B Y1472F knock-in mice. Although the specific
mechanism is still not fully understood, T286 is a key target for CaMK II to initiate its
downstream pathways. This study suggests that CaMK II can also be affected by the
Y1472 site of NR2B (Matsumura, Kunori et al. 2010).
Protein phosphorylation is a process that regulates protein activity. Normally, the
phosphorylation sites can be classified into two classes: serine/threonine and tyrosine
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phosphorylation sites (Chen and Roche 2007). NR2B contains a large intracellular part
with many phosphorylation sites (Chen and Roche 2007, Doshi and Lynch 2009, Qiu,
Li et al. 2011), including several serine/threonine phosphorylation sites, such as S1303,
S1323, and S1480 in the C terminal. S1303 plays a key role in the NR2B-mediated
neurite growth and neuronal plasticity (Chen and Roche 2007, Qiu, Li et al. 2011), and
was shown to be an important position for CaMK II binding by many studies. Since the
mechanism behind the regulation is complicated, it has not yet been fully elucidated.
According to Stack et al., S1303 site phosphorylation reduces the binding of CaMK II
to NR2B (Strack, McNeill et al. 2000). Meanwhile, Liu et al. showed that the CaMK
II-NR2B complex in the striatum dissociates when the phosphorylation of S1303 is
reduced (Liu, Chu et al. 2006).
The NR2B S1303 site is not just a CaMK II binding site, but it was found to be a key
position for dopamine 2 receptor (D2R) binding in the study by Liu et al. This study
pointed out that an increased formation of the D2R-NR2B complex will significantly
reduce the phosphorylation of S1303 in NR2B. This will affect the NR2B binding to
other proteins, such as CaMK II, and thus affect several NR2B-mediated signalling
pathways (Liu, Chu et al. 2006).
In NR2B, serine/threonine phosphorylation sites are not the only positions that can be
phosphorylated. Tyrosine phosphorylation sites, such as Y1336 and Y1472, were also
found to be important for many NR2B-mediated signalling pathways (Chen and Roche
2007). Among these phosphorylation sites, Y1472 is the most well-studied site, with
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several functions already elucidated. In NR2B, Y1472 is within the sequence of YEKL,
which is a tyrosine-based internalization motif (Lavezzari, McCallum et al. 2003). The
Src family kinases, including Fyn and Pyk2, can phosphorylate Y1472 (Nakazawa,
Komai et al. 2001, Bjarnadottir, Misner et al. 2007). When the phosphorylation of
Y1472 is upregulated, this results in a strong inhibition of the endocytosis effect of
NR2B (Nakazawa, Komai et al. 2001, Roche, Standley et al. 2001). In summary, NR2B
can initiate its downstream signalling pathways when it is stable in the membrane. At
the same time, when the phosphorylation of Y1472 is reduced, the endocytosis of NR2B
is increased, and the NR2B-mediated signalling pathways are inhibited.
1.2.2.4 NR2B, CREB, and BDNF signalling pathway
CREB and BDNF are important downstream proteins of the NR2B receptors. The
activation of NMDA receptors in physiological conditions can induce calcium influx.
Then, Ca2+ entry activates CREB (Sala, Rudolph-Correia et al. 2000). CREB is an
important prototypical transcription factor, which is responsible for neuronal survival,
synaptic plasticity, neurogenesis as well as learning, and memory (Alberini 2009,
Kitagawa, Sugo et al. 2017, Landeira, Santana et al. 2018). Many genes were identified
as being the target of CREB, such as the B-cell translocation gene 2, serine protease
inhibitor B2, B-cell lymphoma 6, and BDNF (Hardingham and Bading 2010). Among
these genes, BDNF is an important molecule that can regulate neuronal plasticity,
neuronal growth, and neuronal apoptosis (Kowianski, Lietzau et al. 2018). Once the
CREB is activated by calcium influx, Ser-133 of CREB is phosphorylated in the
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nucleus, increasing the transcription of BDNF in neurons (Nair and Vaidya 2006).
Previous studies showed that the reduction in the BDNF expression can induce synaptic
loss and cognitive dysfunction in the brain (Vaynman, Ying et al. 2004, Leal, Afonso
et al. 2015). Furthermore, in neurodegenerative diseases, such as AD, the modulation
of the CREB expression in the CNS can increase the expression level of BDNF, thus
alleviating the learning and cognitive dysfunction of AD patients (Rosa and Fahnestock
2015). Therefore, CREB and BDNF are important regulators in the NMDA receptorinduced neuroprotection.
However, in many neurodegenerative diseases, NMDA receptors are always
overactivated. It is observed that NR2B is the main component of extrasynaptic NMDA
receptors and extrasynaptic NR2B receptors are abnormally activated in pathological
conditions (Hardingham and Bading 2010). The synaptic and extrasynaptic NR2B
receptors were indeed found to activate different signalling pathways in the neuron
(Gladding and Raymond 2011, Zhou, Hollern et al. 2013). Specifically, the activation
of synaptic NR2B receptors can induce the phosphorylation of CREB and BDNF
expression, which is important for neuronal survival and synaptic plasticity (Nair and
Vaidya 2006). However, the activation of extrasynaptic NR2B receptors initiates many
pro-death signalling pathways, among which the CREB shut-off pathway is one of the
most important ones (Hardingham and Bading 2010, Vizi, Kisfali et al. 2013). One
explanation is that the activation of extrasynaptic NR2B receptors induces a short
augment of CREB phosphorylation at first, followed by a sustained CREB29

dephosphorylation signal afterward (Hardingham, Chawla et al. 1999, Sala, RudolphCorreia et al. 2000). Therefore, many studies observed that the overactivation of
NMDA receptors in extrasynaptic regions leads to an inhibition of CREB
phosphorylation, which further inhibits the transcription of BDNF (Hardingham and
Bading 2002, Kaufman, Milnerwood et al. 2012). Furthermore, studies on AD found
that Aβ causes learning and memory impairments via the CREB-BDNF signalling
pathway (Rosa and Fahnestock 2015). Moreover, the addition of Aβ in the neuronal
culture was shown to cause impairment of the hippocampal LTP and spine density loss.
Pretreatment with BDNF can reverse the Aβ-induced impairment in primary cell
cultures (Criscuolo, Fabiani et al. 2015).
1.2.2.5 NR2B antagonist memantine
Memantine is a well-known NMDA receptor antagonist, which is used in clinical
practice in AD treatment. The exact mechanism of how memantine works in the brain
is still debated (Johnson and Kotermanski 2006). Although memantine has fast
blocking kinetics of the NMDA receptors, it has a low binding affinity (Danysz, Parsons
et al. 2000, Johnson and Kotermanski 2006). Therefore, unlike other potent antagonists
of the NR2B receptors (e.g., MK-801, ifenprodil), memantine is unable to completely
inhibit the activity of the NMDA receptor. Usually, those potent antagonists should
have a better performance if the hyperactivity of the NMDA receptors causes the
problem. However, in AD, memantine is the only compound that showed a significant
therapeutic effect in clinical practice as an NMDA receptor antagonist (Mangialasche,
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Solomon et al. 2010). One possible explanation is that the NMDA receptor is functional
in the brain, such that it induces LTP. A complete blockade of the NMDA receptors
will prevent the normal function of neurons. However, as a partial antagonist,
memantine could prevent the neurotoxicity induced by the hyperactivity of the NMDA
receptors, while still keeping the normal function of the receptor (Chen, Pellegrini et al.
1992, Johnson and Kotermanski 2006, Parsons, Stoffler et al. 2007). Memantine was
shown to mainly prevent the activity of extrasynaptic NR2B receptors (Xia, Chen et al.
2010), which initiate a pro-death signalling pathway when activated (Gladding and
Raymond 2011). On the other hand, memantine has little effect on the synaptic NMDA
receptors, which are responsible for LTP and long-term depression (LTD) in the brain
(Xia, Chen et al. 2010).
1.2.3

NR2B and D2R interaction

1.2.3.1 D2R and its signalling pathway
D2R is a G protein-coupled receptor (GPCR), and its activation can trigger G proteindependent and non-G protein signalling (Beaulieu, Gainetdinov et al. 2009). The
activation of D2R was shown to regulate many second messengers in the cell, including
the potassium, inositol phospholipid, and calcium ion (Pizzi, Da Prada et al. 1988,
Einhorn, Gregerson et al. 1991, Kisilevsky and Zamponi 2008). These second
messengers are critical modulators in the development and survival of neurons.
Therefore, D2R is always considered one of the most vital targets in psychiatric
disorders and neurodegenerative diseases.
31

Glycogen synthase kinase 3 beta (GSK-3β) is an important downstream target of D2R
(Del'guidice, Lemasson et al. 2011). Previous studies showed that D2R could activate
the multifunctional adaptor protein beta-arrestin 2 (Beaulieu, Sotnikova et al. 2005),
which then activates many G protein-independent intracellular signalling cascades,
including the Akt/GSK3 pathway (Beaulieu, Marion et al. 2008). GSK-3β is an
important enzyme for neurite regulation. For example, the work of Garrido et al. found
that GSK-3β is associated with axon formation and branching (Garrido, Simon et al.
2007). Many studies also pointed out that GSK-3β can regulate the phosphorylation of
CREB (Tang, Shi et al. 2014, Wu, Liang et al. 2018). Recently, Barnat et al. have found
GSK-3β to modulate neurite branching via the GSK3–MAP1B pathway (Barnat,
Benassy et al. 2016). The regulation of GSK-3β is unusual compared with other kinases,
and it is inactivated by phosphorylation in Ser-9 (Krishnankutty, Kimura et al. 2017).
It was found that many antipsychotic drugs can promote the phosphorylation of GSK3β, thus inhibiting its activity (Sutton, Honardoust et al. 2007, Mohammad, Al-Masri
et al. 2008). Notably, the D1R agonist of SKF38393 did not change the phosphorylation
of GSK-3β at Ser-9. Therefore, the phosphorylation of GSK-3β is considered as the
target of D2R, but not D1R (Lebel, Patenaude et al. 2009).
1.2.3.2 D2R and neurite growth
Dopamine and its D2R are well known to regulate neurite growth in the brain. However,
the mechanism behind this regulation is complicated. Todd et al. reported that 10 to
1000 nM of quinpirole (D2R agonist) increased neurite length in primary cortical
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neurons, while the D2R antagonists, eticlopride and spiperone, could block this effect
(Todd 1992). Their results suggested that the activation of D2R increases neurite
growth. In a later study, Reinoso et al. indicated that 1 μM of quinpirole stimulated
neurite growth, but 100 μM of quinpirole inhibited neurite length in cortical neurons
(Reinoso, Undie et al. 1996). Furthermore, in schizophrenia patients, D2R was
observed to be overactivated (Zakzanis and Hansen 1998). Therefore, overactivation of
D2R is harmful to the neurons in schizophrenia patients.
1.2.3.3 The interaction between NR2B and D2R
NR2B is known to bind to several GPCRs, among which D2R is one of the most
important receptors (Fan, Jin et al. 2014). Liu et al. studied the long-form of D2R and
found that D2R can physically bind to NR2B in the post synaptic density (PSD) in the
striatum. They also studied the binding area of both proteins. Their results indicated
that the phosphorylation of the NR2B-S1303 site is significantly affected by enhanced
formation of the D2R-NR2B complex, suggesting a high significance of the D2RNR2B interaction on this site. The binding sequence of D2R is a TKRSSRAFRA motif
located in the third intracellular loop of D2R, which is the amino acid position of 225234 (Liu, Chu et al. 2006).
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1.2.4

Quinolinic acid, ROS, and autophagy

1.2.4.1 Excessive quinolinic acid induces ROS production
It is noticed that the production of QA-induced ROS could be either dependent or
independent of the NMDA receptors (Santamaria, Galvan-Arzate et al. 2001, LugoHuitron, Ugalde Muniz et al. 2013, Vandresen-Filho, Martins et al. 2015).
Overactivation of the NMDA receptors causes an augmented calcium influx, which
leads to mitochondrial dysfunction and oxidative stress. In this respect, QA-induced
ROS production happens in an NMDA receptor-dependent manner. On the other hand,
the NMDA-independent pathway includes a QA-iron complex (Perez-De La Cruz,
Carrillo-Mora et al. 2012, Kubicova, Hadacek et al. 2013). Previous studies
demonstrated that this QA-iron complex could increase both ROS and lipid
peroxidation in the cell (Santamaria, Galvan-Arzate et al. 2001). In the presence of Fe2+,
QA can bind with iron through the Fenton reaction while inhibiting Fe2+ oxidation by
the complex formation (Santamaria, Galvan-Arzate et al. 2001). The resulting QA-Fe2+
complex was shown to be essential for the DNA chain breakage in vitro and lipid
peroxidation affected by free hydroxyl radicals (Platenik, Stopka et al. 2001, LugoHuitron, Ugalde Muniz et al. 2013).
Although QA is known to induce the cell death of both neurons and astrocytes, different
mechanisms are involved in these effects (Braidy, Grant et al. 2009). Inflammation and
excessive ROS production are one of the main causes of QA-induced neuronal death
(Santamaria, Galvan-Arzate et al. 2001). Specifically, QA could induce the secretion
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of several proinflammatory cytokines and chemokines, such as interleukin (IL)-1β, IL8, and monocyte chemotactic protein 1 (Guillemin, Croitoru-Lamoury et al. 2003, Ting,
Brew et al. 2009). Meanwhile, QA significantly increases lipid peroxidation in the
neurons (Rios and Santamaria 1991, Santamaria, Galvan-Arzate et al. 2001). The
secretion of these factors in pathological conditions will finally lead to neuron death.
On the other hand, the mechanism of QA-induced astrocyte apoptosis is often
considered to be regulated by the NMDA receptors (Tavares, Tasca et al. 2002, Ting,
Brew et al. 2009), with calcium influx playing an important role. This QA-induced
gliotoxicity could be attenuated by the ion channel blocker MK-801 and NMDAR
antagonist memantine (Tavares, Tasca et al. 2002, Braidy, Grant et al. 2009). Therefore,
these findings suggest that both ROS production and NMDA receptors are involved in
QA-induced toxicity.
1.2.4.2 Quinolinic acid and autophagy
QA is widely accepted to induce autophagy in the brain (Wang, Dong et al. 2009,
Braidy, Brew et al. 2014). Previous studies showed that QA could affect autophagy
through several independent pathways. For example, Wang YR et al. reported QA to
induce autophagy by activating Nuclear Factor kappa-light-chain-enhancer of activated
B (NF-kB) (Wang, Dong et al. 2009), a process in which the Cathepsin L and Beclin 1
proteins are involved. Moreover, Feng W et al. demonstrated that QA-induced
autophagy could also be activated by Tumour Necrosis Factor alpha (TNFα) (Feng,
Wang et al. 2017). Therefore, it is believed that QA could activate autophagy through
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neuroinflammation, which is independent of the NMDA receptor-induced
excitotoxicity. However, several studies also showed that the QA-induced autophagic
process could be attenuated by the NMDA ion channel blockers, such as MK-801 and
memantine (Lugo-Huitron, Ugalde Muniz et al. 2013). Notably, Rahman A. et al.
demonstrated that memantine could protect against QA-induced neuron inflammation
and oxidative stress in rat embryonic hippocampal neurons (Rahman, Al-Qenaie et al.
2019). Since memantine is an NMDA receptor antagonist, this means that NMDA
receptors are involved in inflammation and autophagy, although the mechanism is still
unclear.
1.2.4.3 ROS and autophagy
Excessive ROS can damage cells and organs (Auten and Davis 2009). Even some
organelles in the cell could be vulnerable when too many oxidative products are
accumulated (Guo, Sun et al. 2013). For example, neurons are injured when excessive
ROS production is produced (Wang and Michaelis 2010, Beckhauser, Francis-Oliveira
et al. 2016). The reason is that the total oxygen consumption is significantly higher than
any other organ in the human body, which makes the accumulation of ROS production
much easier. Moreover, neurons contain a large number of mitochondria, which are the
key organelles in the cell to utilize oxygen and produce oxidative stress (Guo, Sun et
al. 2013). Although many other cells also contain many mitochondria for energy
consumption, they have potent antioxidant enzyme activities, such as those for super
oxide dismutase (Angelova and Abramov 2018). Unfortunately, the concentration of
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antioxidant enzymes in the neurons is lower than in most other cells in humans, making
the neurons more vulnerable to excessive ROS production.
The accumulation of ROS leads to serious oxidative stress, which could lead to neurite
lesions and cell death in the brain area (Leutner, Eckert et al. 2001, Wang and Michaelis
2010). Therefore, the autophagy process is increased in many cells to clean up the extra
ROS production to maintain the normal function of these cells, including the neurons
(Filomeni, De Zio et al. 2015, Yun, Jo et al. 2020). For example, many studies indicated
that autophagy could help the cells remove oxidized proteins via the chaperonemediated autophagy pathway (Kiffin, Christian et al. 2004). Moreover, p62 is known
to deliver protein aggregates to the autophagosomes, and these proteins are decomposed
during the autophagy process (Fan, Tang et al. 2010). Meanwhile, p62 increases due to
excessive oxidative stress; thus, many oxidized proteins could be eliminated through
this pathway.
1.2.4.4 ROS and Alzheimer’s disease
At physiological concentrations, ROS plays an important role in regulating several
signalling pathways in the cell (e.g., cell cycle regulation and phagocytosis) (Bae, Oh
et al. 2011). However, when excessive ROS production is accumulated, this could be
seriously harmful to the cells. The risk of ROS-induced damage was shown to increase
with aging (Stefanatos and Sanz 2018). Therefore, ROS is always considered an
important factor in the etiology of neurodegenerative diseases, such as AD.
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ROS has been found to affect many aspects of AD patients. Firstly, mitochondrial
dysfunction is always observed in the case of excessive ROS production in the
mitochondrial (Llanos-Gonzalez, Henares-Chavarino et al. 2019). Many oxidative
substances, such as hydroxyl radical and hydrogen peroxide, are massively produced in
the mitochondrial (Thomas, Mackey et al. 2009). Therefore, the accumulation of these
substances lowers ATP production, which causes mitochondrial damage and is always
accompanied by cell death in AD patients (Guo, Sun et al. 2013). Secondly, the
accumulation of ROS products, especially superoxide radicals, could activate microglia,
which induces inflammation and neuronal lesions in the brain area (Mittal, Siddiqui et
al. 2014). Furthermore, Aβ, which is a key peptide in the development of AD, was also
found to induce oxidative stress in the brain (Schilling and Eder 2011). Massaad et al.
indicated that the amyloid plaque could induce lipid peroxidation in the brain (Massaad
2011). Meanwhile, other studies found an elevation of lipid peroxidation in the
peripheral tissues in AD patients (Rani, Krishnan et al. 2017). Moreover, the expression
level of 4-hydroxynonenal, which is a peroxidation marker, was found to increase with
excessive oxidative stress (Mihalas, De Iuliis et al. 2017).
1.2.4.5 ROS induces neurite lesions
Three mechanisms may explain how ROS induces neurite lesions. The first mechanism
is that ROS induces the oxidation of polyunsaturated fatty acids, which then leads to
membrane curing in neuronal cells (Sies 1997, Watson, Nelson et al. 2012). For
example, previous studies showed that treatment with a low dose of hydrogen peroxide
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induces neurite lesions (Jang and Surh 2001, Fukui, Takatsu et al. 2011, Kwon, Kim et
al. 2012). Moreover, the addition of 2,2'-azobis(2-amidinopropane) dihydrochloride, a
soluble free radical initiator, causes membrane oxidation (Fukui, Sekiguchi et al. 2013).
As a result of membrane oxidation, some membrane receptors, such as the NMDA
receptors, increase their calcium influx. This further increases the ROS production in
the cell and leads to calcium leakage in the mitochondria and endoplasmic reticulum
(ER), which finally damages the cells (Suzuki, Nagai et al. 2012, Vandresen-Filho,
Martins et al. 2015).
The second mechanism is that ROS can damage the formation of cytoskeletal proteins
in the axonal region, which then disrupts the microtubule formation. For example, the
collapsin response mediator protein (CRMP)-2 is known to be important in the
maintenance of microtubule stabilization. Many studies showed that CRMP-2 can be
excessively phosphorylated by GSK-3β and calcium influx, which can both be activated
by ROS (Moutal, Francois-Moutal et al. 2016). Then, axonal dysfunction is caused in
the prefrontal and hippocampal neurons by the massive phosphorylated CRMP-2
(Miyasaka, Morishima-Kawashima et al. 2001). Fukui’s study showed that the
phosphorylated CRMP-2 was significantly increased in aged mice (Fukui, Kawakami
et al. 2012). Meanwhile, CRMP-2 phosphorylation was also upregulated in mice with
vitamin E deficiency. Both mice showed significant neurite lesions and axonal
degeneration (Fukui, Kawakami et al. 2012).
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The third mechanism is based on the ability of ROS to cause mitochondrial dysfunction
in the neuronal cells. As mentioned above, ROS causes a massive calcium influx in the
cell, leading to mitochondrial damage, which is the activator of mitophagy (Frank,
Duvezin-Caubet et al. 2012, Lin and Kuang 2014). Since mitochondria play important
roles in the axonal formation in neuronal cells, mitochondrial dysfunction will affect
the axonal transport system and finally lead to the accumulation of vesicles in the axon
(Shefa, Jeong et al. 2019).
1.2.4.6 The effect of antipsychotic drugs on ROS and autophagy
Antipsychotic drugs are widely used in the treatment of schizophrenia and other
psychiatric disorders, with the main target mostly being dopamine receptors (Kapur and
Remington 2001, Amato, Canneva et al. 2020). However, previous studies showed that
antipsychotic drugs also have other targets, such as serotonin and histamine receptors
(Kim, Huang et al. 2007, Lord, Wyler et al. 2017). Many antipsychotic drugs have
recently been proven to affect ROS and autophagy in neuronal cells (Park, Chung et al.
2012, Vucicevic, Misirkic-Marjanovic et al. 2014). For example, olanzapine is known
to activate autophagy by increasing the LC3 II expression in SH-SY5Y cells.
Risperidone and haloperidol were found to increase autophagic vesicles in SH-SY5Y
cells; whether they can promote the completion of the autophagic process is still unclear
(Vucicevic, Misirkic-Marjanovic et al. 2014). The effect of clozapine is controversial.
Although one recent study has shown that clozapine can increase the LC3 II expression
in the rat frontal cortex via the AMP-activated protein kinase (AMPK) pathway (Kim,
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Park et al. 2018), another work indicated that clozapine could decrease the LC3 II
expression in culture rat neurons due to the autophagy process being incomplete (Park,
Chung et al. 2012). Therefore, the increase in LC3 II could also refer to the
accumulation of LC3 II while the downstream reaction is inhibited. Table 1.1
summarizes the main findings on the effects of different antipsychotic drugs on
autophagy.
Table 1.1 Summary of how antipsychotic drugs induce ROS and autophagy
Antipsychotics

Cells/Tissues

Autophagy

Mechanism

Olanzapine

SH-SY5Y cells

LC3 II ↑

ROS ↑

Vucicevic et al., 2014

Risperidone

SH-SY5Y cells

LC3 II ↑

ROS ↑

Vucicevic et al., 2014

Haloperidol

SH-SY5Y cells

LC3 II ↑

ROS ↑

Park et al., 2012

Clozapine

Frontal cortex

LC3 II ↑

AMPK ↑

Kim et al., 2018

Clozapine

Rat neurons

LC3 II ↓

Autophagosomelysosome ↓

Ref.

Park et al., 2012

Many proteins are known to regulate autophagy in neuronal cells (He and Klionsky
2009). For example, ROS can induce the autophagy process (Filomeni, De Zio et al.
2015, Fang, Gu et al. 2017). However, the exact mechanism is still unclear. It is worth
mentioning that olanzapine, which is an antipsychotic drug, has a direct effect on
autophagy via the ROS-autophagy signalling pathway. This is because intermediate
proteins, such as the mammalian target of rapamycin (mTOR), are not affected in the
presence of olanzapine (Vucicevic, Misirkic-Marjanovic et al. 2014). However, a
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different pathway is triggered by clozapine. Recent studies have shown that clozapine
can activate AMPK in SH-SY5Y cells and primary hippocampal neurons (Kim, Park
et al. 2018). Silencing AMPK by a genetic knockdown reduces the effect of clozapineinduced autophagy. Additionally, the autophagy process is also regulated at the
transcriptional level. Studies on mRNA indicated that the mRNA expression of kinases
that activate autophagy (ATG 4, 5, 7, and 12) is affected by the treatment with
olanzapine (Vucicevic, Misirkic-Marjanovic et al. 2014).
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1.3

Hypotheses and Aims

1.3.1

Hypotheses

1. It is hypothesized that a high concentration of QA causes neurite lesions in neuronal
cells. QA-induced neurite lesions are via the NMDA-NR2B-CREB-BDNF
signalling pathway.
2. It is hypothesized that a reciprocal interaction is at the receptor level between NR2B
and D2R.
3. It is hypothesized that QA can induce ROS and autophagy in neuronal cells, and the
antipsychotic drug olanzapine can inhibit QA-induced ROS.
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1.3.2

Aims

1. To investigate whether excessive QA causes neurite lesions by overactivation of the
NMDA receptors, especially NR2B receptors.
2. To investigate if a direct reciprocal interaction exists between D2R and NR2B at
the receptor level.
3. To investigate if the antipsychotic drug olanzapine can reduce the QA-induced ROS
and autophagy.
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1.4

Significance

Neurodegenerative diseases are a group of debilitating, incurable, and progressive
diseases, among which AD and PD are the most common. Although they have a
complicated mechanisms, these diseases share similar features at the cellular level. In
many neurodegenerative diseases, cognitive impairment and memory loss are key
factors due to neurite lesions in the brain. Previous studies showed that QA is an NMDA
receptor agonist and a potential excitotoxin in the brain. The concentration of QA was
found to increase with age in both animal studies and clinical studies. Some studies also
showed that the concentration of QA can reach micromolar levels in the brain and CSF
in patients with AD. Therefore, investigating the effects of excessive QA could
contribute to understanding the mechanism of excessive QA-induced neurite lesions.
Furthermore, detecting the downstream proteins of the NMDA receptors helps to have
a better understanding of the signalling pathway of QA-induced neurotoxicity.
It is worth noting that QA-induced hyperactivity of NMDA receptors might be the cause
of neurotoxicity in neurodegenerative diseases and the QA-induced excessive ROS.
Excessive ROS in neuronal cells plays an important role in developing
neurodegenerative diseases since mitochondrial dysfunction and inflammation are
always observed in this case. Additionally, excessive ROS production is also linked
with neurite lesions and axon formation impairment. Therefore, understanding the
mechanism of QA-induced ROS and autophagy is important to finding new
therapeutical methods for neurodegenerative diseases.
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1.5
1.5.1

General Methods
Antibodies and chemicals
Table 1.2 Summary of the materials used in the project study
Reagent

Source

Identifier

Rabbit monoclonal anti-NR2B

Abcam

ab183942

Mouse monoclonal anti-CaMKII-α

Cell Signaling

50049

Rabbit monoclonal anti-CREB

Cell Signaling

4820

Rabbit monoclonal anti-pCREB

Cell Signaling

9198

Rabbit monoclonal anti-BDNF

Cell Signaling

47808

Mouse monoclonal anti-PSD-95

Invitrogen

Mouse monoclonal anti-β-actin

Millipore

Rabbit monoclonal anti-GSK3β Ser9

Cell Signaling

5558

Rabbit monoclonal anti-GSK3α/β

Cell Signaling

5676

Mouse monoclonal anti-D2R

Santa Cruz

Rabbit monoclonal anti-NR2B Y1472

Cell Signaling

Donkey anti-mouse Alexa Fluor 488

Invitrogen

A21202

Donkey anti-rabbit Alexa Fluor 568

Invitrogen

A10042

Goat anti-rabbit Alexa Fluor 488

Invitrogen

A11008

Goat anti-mouse Alexa Fluor 568

Invitrogen

A11004

Rabbit monoclonal anti-LC3b

Cell Signaling

2775

Rabbit monoclonal anti-SQSTM1/p62

Cell Signaling

5114

Antibodies

516900
MAB1501

sc-5303
4208

Chemicals
Quinolinic acid

Cayman

14941

Ifenprodil

Sigma

I2892

MK-801

Sigma

M107

Memantine

Cayman

14184

Quinpirole hydrochloride

Sigma

Q102

Haloperidol

Cayman

12014

Olanzapine

Cayman

11937
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DMEM/F12

Thermofisher

11320033

Fetal Bovine Serum

Thermofisher

26140079

Penicillin-Streptomycin

Thermofisher

15140148

Neurobasal® Medium

Thermofisher

21103049

B27 Supplement

Thermofisher

17504044

ProLong™ Diamond Antifade Mountant

Thermofisher

P36961

Trypsin inhibitor

Sigma

T9253

Poly-D-Lysine

Sigma

P7280

Donkey serum

Sigma

D9663

Recobinant DNA
NR2B plasmid

GeneScript

N/A

NR2B siRNA

RiboBio

N/A

D2R siRNA

RiboBio

N/A

Dyes
H2DCFDA

Thermofisher

D399

MitoSOX

Thermofisher

M36008

Acridine orange

Sigma

318337

Expeirmental Models

1.5.2

Primary striatal neurons

C57BL/6J

SH-SY5Y neuroblastoma cells

ATCC

N/A
CRL2266

Cell culture

Neuroblastoma SH-SY5Y cells were grown in DMEM/F12 (Life Technologies,
Carlsbad, USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillinstreptomycin (Thermo Fisher, Waltham, USA) in 5% CO2 incubator at 37 °C. Cells
were cultured in T75/T25 flasks for 3-5 days to reach 70% confluence. Cells were then
either sub-cultured for future use or plated for experiments. 10 μM retinoic acid (RA)
was used to induce differentiation of SH-SY5Y cells. For differentiation experiments,
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SH-SY5Y cells were differentiated using DMEM/F12 with 1% of FBS while
supplemented with 10 μM all-trans-RA.
1.5.3

Cell viability assay

Neuroblastoma SH-SY5Y cells were seeded in a 96-well plate. Cells were treated with
compounds or drugs for 24 h before measurement. Cell viability was measured by the
MTT viability assay. Cells were treated with MTT dye for 10 mins at 37°C before
reading. Then plates were put in a plate reader and measured at 570 nm to get
fluorescence intensity.
1.5.4

Neurite outgrowth/extension assay

Cells were plated in a 96-well plate at a density of 2*104 cells/mL for the neurite growth
and impairment experiments. After treating with compounds of interest, cells were put
in the incucyte machine. Images were taken every 4 or 6 hours from the beginning
(depending on the experiment design). The neurites were analysed using the Neurotrack
software. Considering the cell density cannot be even in each well, Neurite length per
cell body cluster was used to reflect the extension level of neurites.
1.5.5

Transfection assay

Cells were treated with DMEM/F12 containing 1% FBS with 1mM RA 24 h before
transfection. The NR2B plasmid was synthesized by GenScript (GenScript, Hong Kong
Ltd). The NR2B siRNA and D2R siRNA was synthesized by RiboBio (RiboBio,
Guangzhou Ltd). Transfection was performed using Lipofectamine 2000 (Life
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Technologies) according to the manufacturer’s instructions. The neurites were
measured immediately after transfection. After 6 h, the culture medium was changed to
DMEM/F12 complemented with 1% FBS and 10 μM RA to stop the transfection. The
neurites were continually measured for at most 48 hours.
1.5.6

Primary cell culture

Primary striatal neurons are from brain tissues of postnatal day 0 (PN0) mice. All
experimental procedures have been approved by the Animal Ethics Committee,
University of Wollongong, Australia. Briefly, dissociated striatal neurons were seeded
at a final density of 2.5 × 105 cells/cm2, onto poly-D-coated 24-well plates, containing
neurobasal media (NBM) supplemented with B27. 5-Fluoro-2′-deoxyuridine (5-FDU)
is added into the medium to prevent the growth of non-neuronal cells including
astrocytes and microglia. Cultures were cultured in a humidified CO2 incubator at 37 ̊C.
The culture medium was changed every 2-3 days. Primary cells can be used for
experiments after 7-10 days in vitro.
1.5.7

Western Blot

The whole procedure of western blot follows the protocol in our lab. Briefly, tissue
samples are separated by SDS-polyacrylamide gel electrophoresis using pre-cast 10%
Tris-Glycine gels (Invitrogen) and then electroblotted onto a polyvinylidene difluoride
membrane (PVDF) for 2 hours and 15 minutes. Membranes are blocked with Trisbuffered saline with Tween-20 (TBS-T) containing 5% milk at room temperature for
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an hour and then incubated with primary antibodies at 4°C for 12 hours. Membranes
are then washed in TBS-T and incubated at room temperature for 2 hours with speciesspecific secondary antibodies. The detection of proteins conjugated with antibodies is
performed with chemiluminescence. Blots are exposed to film, and signal intensity is
quantified relative to the loading control β-actin, using Image J software.
1.5.8

Fluorescence resonance energy transfer (FRET)

For D2R-NR2B interaction, anti-D2R-Alexa Fluor 488 was used as a donor dipole and
anti-NR2B-Alexa Fluor 568 was used as an acceptor dipole. 488 nm is set as the
excitation wavelength and 603 nm is set as the emission wavelength. Primary cells were
analysed by using the Leica application wizard for FRET.
1.5.9

ROS production

The intracellular ROS and mitochondrial ROS were measured by flow cytometry, using
a BD Accuri™ C6 Plus Flow Cytometer (BD Biosciences). The cell-permeant 2',7'dichlorodihydrofluorescein diacetate (H2DCFDA) (Thermofisher Scientific, D399)
was used to measure the intracellular ROS, and MitoSOX Red Mitochondrial
Superoxide Indicator (ThermoFisher Scientific, M36008) was used to measure
mitochondrial ROS. After 15 min treatment with H2DCFDA, cells were washed in
phosphate-buffered saline (PBS). Cells were then mixed and collected in a 1.5 mL
Eppendorf tube. FITC (fluorescein isothiocyanate), corresponding to intracellular ROS
levels, was determined by flow cytometry.
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1.5.10 Acridine orange (AO) staining
pH-sensitive dye acridine orange (AO) (Sigma-Aldrich, 318337) was used to determine
the number of intracellular acidic vesicles. BD Accuri™ C6 Plus Flow Cytometer (BD
Biosciences) was used for the measurement. Flow cytometric analysis was measured as
previously described.
1.5.11 Statistical analysis
Statistical analysis was performed using the SPSS program (version 21; Chicago, IL,
United States). Two-way analysis of variance (ANOVA) was used for dose-response
and time-response curves. A normality test was performed for confirmation of data in
normal distribution. Student t-test was used when only two groups were compared.
ANOVA was used for three and more group comparisons, followed by posthoc multiple
comparisons. Data were expressed as mean ± SEM, and p < 0.05 was considered
statistically significant.
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1.6
1.6.1

Overview of the thesis
Quinolinic

acid

induces

neurite

lesions

via

NMDA

receptor

hyperactivation
QA can induce neurite lesions in the brain. Although excessive QA was previously
demonstrated to be deleterious to the neurons, the exact mechanism is complex and still
not fully understood. This study investigated the signalling pathway of QA through the
NMDA receptors. I found that QA caused serious neurite lesions in a dose- and timedependent manner. Although the expression level of NR2B was not significantly
affected by QA, its downstream proteins of pCREB and BDNF were significantly
reduced. This effect was dependent on NMDA receptors because MK-801 and
ifenprodil attenuated QA-induced neurite lesions, suggesting the involvement of NR2B
receptors. Moreover, memantine, which is an uncompetitive antagonist of NMDA
receptor, also reduced QA-induced neurite lesions. Furthermore, NR2B siRNA was
used to block the NMDA signalling pathway, which also resulted in attenuating QAinduced neurite lesions. Taken together, these results suggest that excessive QA causes
neurite lesions by overactivation of the NMDA receptors and their downstream proteins
of CREB and BDNF.
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1.6.2

Reciprocal regulation between NR2B and D2R in neurite lesions

Previous research showed that the activation of D2R affects NR2B-mediated signalling,
which is relevant to the maintenance of neurite integrity. However, the mechanism is
still unclear. Therefore, investigating the mutual effect between D2R and NR2B in
neurite growth regulation is important for the therapy of neurodegenerative diseases. In
this study, I used quantitative cell imaging, western blot, and interaction techniques.
Results showed that both NR2B overexpression and D2R inhibition can cause neurite
lesions. Furthermore, using the FRET technique, I found the NR2B-D2R interaction to
be enhanced by the D2R hyperactivity. This study showed that neurite lesions caused
by the NR2B overstimulation were not only an overactivation of NR2B-Y1472 and
CaMKII but also an inhibition of D2R. Conversely, this was also true in the existence
of D2R hypofunction leading to NR2B hyperfunction and neurite impairment. In
conclusion, this study uncovered that NR2B hyperactivity induced by D2R
hypoactivity, or vice versa, may induce additional effects causing neurite lesions.
Therefore, a balanced regulation between D2R and NR2B may be an important strategy
for new drug development in treating severe mental diseases.
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1.6.3

Quinolinic acid-induced ROS is prevented by ifenprodil and olanzapine

QA can induce neurite lesions in the brain. Previous studies demonstrated that excessive
QA induces the overactivation of NMDA receptors and the formation of ROS, with no
clear mechanism though. This study investigated the effect of QA on ROS and
autophagy. I found that excessive QA caused a significant ROS increase in neuronal
cells, accompanied by inducing autophagy. The rising of p62 and LC3b-II suggested
an impairment of the autophagy process. NR2B antagonist ifenprodil prevented this
excessive QA-induced ROS production. A low dose of olanzapine also decreased ROS,
while high dose of olanzapine showed no effect. Moreover, 1 μM of olanzapine reduced
p62 but not LC3b-II in SH-SY5Y cells, suggesting that 1 μM of olanzapine restored
autophagy. Taken together, these results suggest that excessive QA increased ROS and
impaired autophagy in neuronal cells, while NR2B antagonist and low dose olanzapine
prevented this impairment.
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1.6.4

Identification of signalling pathways in NR2B loss of function cells by
integrated bioinformatics analysis

NR2B hypofunction is a pathology of schizophrenia. The mechanism of action is still
largely unknown while several hypotheses have been made. In this study, genes
differentially expressed between NR2B loss of function and control human cells were
identified and used to construct protein-protein interaction networks showing closely
related genes. GO enrichment and KEGG analyses were used to investigate the
pathways associated with the DEGs. In conclusion, the present study suggests that the
genes associated with neuronal differentiation, ROS, and cell cycle are significantly
changed due to NR2B LOF. Furthermore, I report that the IGF1R-FOXO pathway is
altered due to NR2B loss of function. My findings may offer a systematic approach for
a better understanding of the neuropathology of NMDAR hypofunction relevant to
schizophrenia.
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1.7

Summary

In summary, this study investigated neurite lesions induced by QA. In Chapter 2, I
studied how a high concentration of quinolinic acid could cause neurite lesions in SHSY5Y cells, in which NMDA receptors are involved. A decrease in the expression of
CREB and BDNF reveals a possible signalling pathway that quinolinic acid works on.
This may represent another aspect of the KP in regulating neuronal activity. The
blockade effect of memantine further confirms that NMDA receptors are important
targets in neurodegeneration diseases.
In Chapter 3, results revealed a direct reciprocal interaction between D2R and NR2B at
the receptor level. I found that the NR2B hyperactivity caused an upregulation of GSK3β, which was upregulated during the inhibition of D2R. On the other hand, the D2R
hypoactivity could directly increase the phosphorylation of Y1472 and the expression
of NR2B, which suggested that NR2B activity can be regulated by D2R. Moreover, I
found that the phosphorylation of NR2B Y1472 also changed due to the inhibition of
D2R, which suggested that D2R also affected the NR2B distribution in the cell
membrane.
In Chapter 4, I found that excessive QA increased ROS production in cells. In addition,
the autophagy process was also affected due to increased QA. Both NR2B antagonists
and low dose olanzapine can reduce QA-induced ROS and autophagy in SH-SY5Y
cells, as well as neurite impairment. These results revealed that both NR2B antagonists
and olanzapine were involved in the regulation of QA-induced ROS production.
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In Chapter 5, I identified the key genes and pathways that were significantly changed
due to NR2B LOF. NR2B LOF can alter the regulation of neuronal differentiation,
ROS-autophagy, and cell cycle significantly. I also found that the IGF1R-FOXO
pathway is altered due to NR2B loss of function, which might be associated with the
pathology of schizophrenia.
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Chapter Two
Quinolinic acid induces neurite impairment via NMDA
receptor hyperactivation
2.1

Abstract

Increased QA is known to induce neurite lesions in the brain, but the exact mechanism
behind this effect is complex and not fully understood yet. This study investigated the
signalling pathway of QA through the NMDA receptors. I found that QA caused serious
neurite lesions in a dose- and time-dependent manner. In addition, QA significantly
reduced its downstream proteins of CREB and BDNF. MK-801 and ifenprodil
effectively attenuated QA-induced neurite lesions, suggesting that the NR2B receptors
were involved. Moreover, the uncompetitive antagonist of the NMDA receptor of
memantine also reduced QA-induced neurite lesions. Furthermore, I blocked the NR2B
receptor using NR2B siRNA, which also attenuated QA-induced BDNF reduction and
neurite lesions. All in all, these results suggest that excessive QA caused neurite by
overactivation of the NMDA receptor and its downstream proteins of CREB and BDNF.
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2.2

Introduction

AD is a chronic progressive neurodegenerative disease. Although the exact mechanism
is complex and not fully understood, it is known that many factors contribute to the
formation of AD. Among these factors, QA was demonstrated to induce neuronal and
astrocytic apoptosis in many aspects (Guillemin, Wang et al. 2005, Braidy, Grant et al.
2009, Lugo-Huitron, Ugalde Muniz et al. 2013). Firstly, QA was proven to be
neurotoxic. Schwarcz and coworkers found that QA causes selective neuronal
impairment (Schwarcz and Du 1991). Besides, the injection of external QA into the
brain induces pathological changes in the striatum. Several studies showed that QA acts
selectively at the NMDA receptors, especially for the NR2A and NR2B subunits (LugoHuitron, Ugalde Muniz et al. 2013, Vandresen-Filho, Severino et al. 2015). The
excessive amount of QA can overactivate NMDA receptors, causing massive calcium
influx into the neurons and astrocytes, which is neurotoxic to the cells (Braidy, Grant
et al. 2009)., Since NMDA receptors are widely distributed in the hippocampus and
striatum, these areas are very vulnerable to the injection of QA (Vandresen-Filho,
Martins et al. 2015).
QA has been proven to inhibit glutamate reuptake and increase its release in the brain
(Braidy, Alicajic et al. 2021). Previous studies also indicated that QA prevents
glutamate metabolism by inhibiting glutamine synthetase activity (Ting, Brew et al.
2009). Therefore, QA does not only increase calcium influx by activating NMDA
receptors, but also by upregulating the glutamate concentration, which exacerbates the
calcium-induced neurotoxicity.
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The glutamate hypothesis is a well-accepted theory in the neuropathology of
neurodegenerative diseases (Olney, Newcomer et al. 1999). The main receptors of the
glutamatergic system are NMDA receptors. Studies showed that NMDA receptors are
hyperactivated in neurodegenerative diseases. This might be due to the activation of
extrasynaptic NMDA receptor signalling pathways, which inhibits the phosphorylation
of CREB and thus affects its downstream genes, such as BDNF. Decreasing pCREB
and BDNF finally leads to neurite lesions in the brain.
The present study showed that QA, which is an NMDA receptor agonist, induced
neurite lesions and inhibited CREB phosphorylation and BDNF expression. These
effects were prevented by adding NR2B receptor antagonists and NR2B siRNA. It is
worth noting that memantine, which is a drug for AD treatment, significantly attenuated
QA-induced neurite lesions, which might be useful for understanding the mechanism
of AD.
2.3
2.3.1

Materials and Methods
Antibodies and chemicals

Quinolinic acid (Cayman, 14941), MK-801 (Sigma Aldrich, St Louis, Missouri, USA),
ifenprodil (Sigma Aldrich, St Louis, Missouri, USA), memantine (Cayman, 14184),
anti-CREB (1:1,000; Cell Signaling Technology, Danvers, USA), anti-phospho-CREB
(1:1000; Cell Signaling Technology, Danvers, USA), anti-BDNF (1:1000; Cell
Signaling Technology, Danvers, USA), anti-β-actin (1:5000; Millipore, Bedford, USA),
anti-NR2B (1:1000, ab28373, Abcam), anti-PSD 95 (1:1000, Invitrogen), Alexa Fluor
488-conjugated goat anti-mouse IgG secondary antibody (1:400; Invitrogen) and Alexa
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Fluor 568-conjugated goat anti-rabbit IgG secondary antibody (1:400; Invitrogen).
NR2B siRNA were synthesized and purchased from RiboBio (RiboBio Techonology,
China), and dissolved in ultrapure water to reach a stock concentration of 10 mM.
2.3.2

Cell culture

Neuroblastoma SH-SY5Y cells were grown in DMEM/F12 (Life Technologies,
Carlsbad, USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillinstreptomycin (Thermo Fisher, Waltham, USA) in 5% CO2 incubator at 37 °C. Cells
were cultured in T75/T25 flasks for 3-5 days to reach 70% confluence. Cells were then
either sub-cultured for future use or plated for experiments. 10 μM retinoic acid (RA)
was used to induce differentiation of SH-SY5Y cells. For differentiation experiments,
SH-SY5Y cells were differentiated using DMEM/F12 with 1% of FBS while
supplemented with 10 μM all-trans-RA.
2.3.3

Cell viability assay

Neuroblastoma SH-SY5Y cells were seeded in a 96-well plate. Cells were treated with
compounds or drugs for 24 h before measurement. Cell viability was measured by the
MTT viability assay. Cells were treated with MTT dye for 10 mins at 37°C before
reading. Then plates were put in a plate reader and measured at 570 nm to get
fluorescence intensity.
2.3.4 Neurite outgrowth/extension assay
In order to study the neurite growth of control and treated SH-SY5Y cells, the cells
were plated in 96-well plates at a density of 2*104 cells/mL. After treating with
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compounds of interest, the cells were put in the IncuCyte machine. Images were taken
every 4-6 h. The neurites were analyzed using the NeuroTrack software. Considering
that the cell density cannot be even in each well, I used the neurite length per cell body
cluster to reflect the extension level of neurites.
2.3.5

Transfection assay

Cells were treated with DMEM/F12 containing 1% FBS with 1mM RA 24 h before
transfection. The NR2B siRNA was synthesized by RiboBio (RiboBio, Guangzhou
Ltd). Transfection was performed using Lipofectamine 2000 (Life Technologies)
according to the manufacturer’s instructions. The neurites were measured immediately
after transfection. After 6 h, the culture medium was changed to DMEM/F12
complemented with 1% FBS and 10 μM RA to stop the transfection. The neurites were
continually measured for at most 48 hours.
2.3.6

Primary cell culture

Primary striatal neurons are from the brain tissues of PN0 mice. All experimental
procedures have been approved by the Animal Ethics Committee, University of
Wollongong, Australia. Briefly, dissociated striatal neurons were seeded at a density of
2.5 × 105 cells/cm2, onto poly-D precoated 24-well plates, containing neurobasal media
(NBM) supplemented with B27. 5-Fluoro-2′-deoxyuridine (5-FDU) is added into the
medium to prevent the growth of non-neuronal cells including astrocytes and microglia.
Cells were cultured in a humidified CO2 incubator at 37 ̊C. The culture medium was
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changed every 2-3 days. Primary cells can be used for experiments after 7-10 days in
vitro.
2.3.7

Western blot

The whole procedure of western blot followed the protocol in our lab. Briefly, tissue
samples were separated by SDS-polyacrylamide gel electrophoresis using pre-cast 10%
Tris-Glycine gels (Invitrogen). Then, they were electroblotted onto a polyvinylidene
difluoride membrane (PVDF) for 2 h and 15 m. The membranes were blocked with
TBS-T containing 5% milk at room temperature for 1 h and then incubated with primary
antibodies to CREB, p-CREB, BDNF, and PSD95 for 12 h at 4 °C. Then, the
membranes were washed in TBS-T and incubated at room temperature for 2 h with
species-specific secondary antibodies. The detection of proteins conjugated with
antibodies was performed using chemiluminescence. The blots were exposed to film,
and signal intensity was quantified relative to the loading control β-actin, using the
ImageJ software.
2.3.8

Statistical analysis

Statistical analysis was performed using the SPSS program (version 21; Chicago, IL,
United States) and the GraphPad Prism 7 software (GraphPad Software, Inc., La Jolla,
CA, USA). One-way analysis of variance (ANOVA) was used respectively for doseresponse and time-response curves. Student t-test was used when only two groups were
compared. ANOVA was used when analyzing three or more groups. Data were
expressed as mean ± SEM, and p < 0.05 was considered statistically significant.
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2.4
2.4.1

Results
Excessive quinolinic acid-induced neurite lesions in a dose and timedependent manner

Increased QA was associated with cognitive deficits in mental illnesses such as
schizophrenia and AD (Guillemin, Brew et al. 2005, Cathomas, Guetter et al. 2021).
Therefore, I investigated whether excessive QA caused neurite lesions. Results show
that QA significantly induced neurite lesions when its concentration reached 25 μM,
while the cells treated with QA at a concentration below 10 μM did not show any
significant impairment in SH-SY5Y cells (Fig 2.1A). On the other hand, a high dose of
QA caused serious neurite damage to SH-SY5Y cells, although the cells were seen to
tightly adhere to the plates, and no significant cell death was observed. These results
showed that QA impaired neurites in SH-SY5Y cells in a dose-response relationship.
Since the concentration of 100 μM showed the most significant neurite reduction, while
no significant cell death was observed in the MTT assay, I decided to use 100 μM QA
for the following experiments. Furthermore, SH-SY5Y cells treated with 100 μM QA
showed significant neurite impairment in 24 h, and the extension of time did not
significantly improve the phenomenon. Therefore, I decided to treat the cells for 24 h
in the following experiments.
To further confirm that excessive QA caused neurite lesions, a neurite-scratch assay
was used to examine the effect of QA on neurite regeneration after injury. The results
showed that the neurite regeneration was significantly reduced after 100 μM QA
treatment (Fig 2.1F, G), suggesting that the QA reduces neurite regeneration.
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Fig. 2.1 QA inhibits neurite outgrowth. (A) Neurite length at various QA concentrations
after 24 h treatment in SH-SY5Y cells. (B) Neurite length was reduced by treatment
with 50 µM and 100 µM of QA in SH-SY5Y cells at various time points, 300 µM
Glutamate (Glu) was used as a positive control. (C) MTT assay of various
concentrations of QA. (D) Representative images of cells with (100 µM) and without
(0 µM) QA treatments in SH-SY5Y cells (n = 5-6, run in triplicate). (E) Quantification
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of QA-induced neurite lesions. (F) Representative images of cells with (100 µM) and
without (0 µM) QA treatments in cortical neurons. (G) Neurite length was not
regenerated at 100 µM QA treatments in primary cortical cells for 72 h (n = 3-4, run in
triplicate). The data are presented as average means ± S.D. *** p < 0.001 vs. control
group.
2.4.2

CREB and BDNF expression in SH-SY5Y cells was reduced by 100 μM
quinolinic acid

To find out the downstream mechanism behind the QA-induced neurotoxicity at the
concentration of 100 μM, the expression level of NMDA receptors downstream
proteins was analyzed after 24 h treatment in SH-SY5Y cells. Results showed that both
pCREB and BDNF were significantly reduced after 12 h or 24 h of QA treatment (Fig
2.2 A and B). Moreover, the expression level of PSD95 confirmed that the neurite was
retracted because of excessive QA (Fig 2.2 C). Overall, these results illustrated that the
QA-induced neurite impairment could be caused by the inhibitory effect on the pCREB
and BNDF expression.
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Fig. 2.2 QA at the concentration of 100 μM affected the expression of the NMDA
receptor downstream proteins of CREB and BDNF in SH-SY5Y cells. (A)
Representative western blots showing protein expression of pCREB/CREB incubated
with 100 μM QA for 3 h, 12 h, and 24 h. (B) Bar Charts of the analysis of pCREB/CREB
protein expression. (C) Representative western blots showing protein expression of
BDNF incubated with 100 μM QA for 3 h, 12 h, and 24 h. (D) Bar Charts of the analysis
of BDNF protein expression. (E) Representative western blots showing protein
expression of PSD95, which indicated the post-synaptic neurite length in SH-SY5Y
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cells. (F) Bar Charts of the analysis of PSD95 protein expression. N ≥ 3, the data are
presented as average means ± S.D. * p < 0.05; *** p < 0.001 vs. control group.
2.4.3

The neurite lesions caused by NR2B hyperactivity were prevented by
NR2B antagonists

To confirm whether QA-caused neurite lesions happen through activating the NMDA
receptors, I used the NMDA receptor antagonist MK-801 and NR2B specific antagonist
ifenprodil to detect whether excessive QA-induced neurite lesions could be prevented.
Results showed that for both compounds, neurite lesions were attenuated after 24 h (Fig.
2.3). These results strongly suggest the involvement of the NMDA receptor, especially
NR2B receptors, in this QA-induced neurite lesions.

Fig. 2.3 QA-induced neurite lesions were prevented by 20 µM of MK-801 and 10 µM
of ifenprodil. (A) Neurite length was reduced when treating with 100 µM of QA in SHSY5Y cells for 24 h, and this neurite lesions were prevented by 20 µM of MK-801 (n
= 3-4, run in triplicate). (B) Representative images of the cells w/o QA and MK-801
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treatments in SH-SY5Y cells (Scale bar = 50 µm); (C) Neurite length was reduced when
treating with 100 µM of QA in SH-SY5Y cells for 24 h. and this neurite lesions could
be prevented by 10 µM of ifenprodil (n = 3-4, run in triplicate). (D) Representative
images of the cells w/o QA and ifenprodil treatments in SH-SY5Y cells (Scale bar = 50
µm). The data are presented as average means ± S.D. * p < 0.05 vs. control group; # p
< 0.05, ### p < 0.001 vs. QA group.
Furthermore, QA was found to be increased in many neurodegenerative diseases, and
memantine is a known drug as an NMDA receptor antagonist for the treatment of AD
(Johnson and Kotermanski 2006). Therefore, it is very important to know the
therapeutic effect of memantine on QA-induced neurite lesions. I found that in both cell
lines and primary cells, neurite lesions were prevented after adding low dose memantine
(Fig. 2.4). These results suggested that memantine can prevent this QA-induced
excitotoxicity in neurons.
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Fig. 2.4 QA-induced neurite lesions were prevented by 1 µM of memantine. (A) Neurite
length was reduced when treated with 100 µM of QA in primary striatal neurons for 24
h, and this neurite lesions could be prevented by 1 µM of memantine (n = 3-4, run in
triplicate). (B) Representative images of the cells w/o QA and memantine treatments in
primary striatal neurons (Scale bar = 50 µm). (C) QA (100 µM) decreased the neurite
length/cell in SH-SY5Y cells, and this neurite lesions were prevented by 1 µM of
memantine (n = 4, run in triplicate). (D) Representative images of the cells w/o QA and
memantine treatments in SH-SY5Y cells (Scale bar = 50 µm). The data are presented
as average means ± S.D, * p < 0.05; ** p < 0.01 vs. control group; # p < 0.05 vs. QA
group
2.4.4

The neurite lesions caused by NR2B hyperactivity were prevented by
NR2B siRNA

Since memantine is not a specific antagonist of NR2B, it is important to confirm that
the QA-induced neurite lesions happened exactly through the NR2B signalling
pathways. Therefore, NR2B siRNA was added to reduce the expression of NR2B in
SH-SY5Y cells. The reduction of NR2B receptors could directly silence the NR2Brelated signalling pathways without affecting other receptors or proteins. Results
showed that NR2B siRNA prevented neurite lesions induced by 100 μM of QA in SHSY5Y cells after 24 h (Fig 2.5 C and D). These results further confirmed that NR2B is
involved in QA-induced neurite lesions. In addition, this result strongly suggested that
QA-induced neurite lesions are caused by NR2B excitotoxicity.
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Fig. 2.5 QA-induced neurite lesions were prevented by NR2B siRNA in 24 h. (A)
Representative western blot showing the protein expression of NR2B w/o NR2B
siRNA. (B) Bar charts of the analysis of the NR2B protein expression. (C) Neurite
length was reduced when treated with 100 µM of QA in SH-SY5Y cells for 24 h, and
this can be prevented by NR2B siRNA (n = 4-6, run in triplicate). (D) Representative
images of cells with QA (100 µM) and with/without siRNA (5 pmol) treatments in SHSY5Y cells; * p < 0.05, ** p < 0.01 vs. control group; # p < 0.05 vs. QA group; Scale
bar = 100 µm.
2.4.5

Quinolinic acid-induced CREB and BDNF change were inhibited by
memantine

After providing a possible signalling pathway for QA-induced excitotoxicity in SHSY5Y cells, I investigated whether memantine could affect this NR2B-CREB-BDNF
signalling pathway. Results showed that low dose memantine effectively prevented
CREB de-phosphorylation and BDNF reduction (Fig. 2.6). Therefore, the results
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suggest that memantine prevented excessive QA-induced neurite lesions via the NR2BCREB-BDNF signalling pathway.

Fig. 2.6 QA-induced BDNF and p-CREB inhibition were prevented by memantine in
SH-SY5Y cells. (A) Representative western blots showing the protein expression level
of p-CREB and CREB. (B) Bar charts of the p-CREB/CREB analysis. (C)
Representative western blots showing the protein expression of BDNF. (D) Bar charts
of the BDNF protein expression analysis. The data are presented as means ± S.D. **p
< 0.01, vs. control group; ## p < 0.01, ### p < 0.001 vs. QA group
2.4.6

Quinolinic acid-induced CREB and BDNF change were inhibited by NR2B
siRNA

To further confirm the involvement of NR2B in the QA-induced NR2B-CREB-BDNF
signalling pathway, I detected CREB and BDNF expression after adding NR2B siRNA
72

to block the effect of QA. Western blot assay was used to determine the protein level
of p-CREB and BDNF. Results indicated that NR2B siRNA can prevent this QAinduced reduction of p-CREB and BDNF (Fig. 2.7). These results suggest that NR2B
is a key receptor that causes p-CREB and BDNF reduction after treatment with a high
dose QA.

Fig. 2.7 QA-induced p-CREB and BDNF inhibition were prevented by NR2B siRNA
in SH-SY5Y cells. (A) Representative western blots showing the protein expression of
p-CREB and CREB. (B) Bar charts of the p-CREB/CREB (C) Representative western
blots showing the BDNF protein expression. (D) Bar charts of the BDNF protein
expression analysis. The data are presented as means ± S.D. **p < 0.01 vs. control
group; ##p < 0.01, ###p < 0.001 vs. QA group.
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2.5

Discussion

In this study, I found that QA-induced overstimulation in neuronal cells caused neurite
impairment. NMDA receptor downstream proteins, CREB, and BDNF were
significantly affected by excessive QA. NMDA receptor antagonists ifenprodil, MK801, and memantine rescued QA-induced neurite lesions. Notably, NR2B siRNA also
reduced neurite lesions caused by excessive QA, which suggested the involvement of
NR2B receptors.
QA is known as a neurotoxin and causes cognitive deficits with a high dose (LugoHuitron, Ugalde Muniz et al. 2013). In many neurodegenerative patients, neurite lesions
always accompany the increase of QA (Gulaj, Pawlak et al. 2010). In the present study,
I found that QA-caused neurite lesions were dose- and time-dependent. Only high dose
QA showed neurotoxicity. This is consistent with previous findings. It was shown that
in Alzheimer’s disease, the concentration of QA can reach micromolar levels in the
brain and CSF (Ting, Brew et al. 2009). Guillemin's study reported that the injection of
Aβ 1-42 could lead to an increase of QA in 72 h (Guillemin and Brew 2002). It is worth
noting that Hernandez-Martinez and his colleague reported that QA at a low dose (50150 nM) could induce differentiation and neuritogenesis in SH-SY5Y cells
(Hernandez-Martinez, Forrest et al. 2017). In their work, the cell viability assay also
showed that a high dose of QA led to cell death instead of cell growth, which is
consistent with my results. Taken together, my results suggest excessive QA is
neurotoxic and induces neurite lesions in neuronal cells.
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QA affects many targets in the brain. For example, QA was found to induce free radical
production, such as ROS and lipid (Rodriguez-Martinez, Camacho et al. 2000, PerezDe La Cruz, Carrillo-Mora et al. 2012). Although I have measured the ROS change in
SH-SY5Y cells after QA treatment (data not shown), a more significant change in
BDNF was found in this study. Therefore, BDNF plays a much more important role
than ROS in QA-induced neurite lesions. We found that pCREB and BDNF were
significantly reduced due to the increase of QA, while the blockade of NR2B receptors
could effectively increase BDNF expression and alleviated QA-induced neurite lesion.
These results can be explained by NR2B-induced excitotoxicity. Overactivation of
NMDA receptors shuts off CREB and decreases its downstream BNDF expression
(Hardingham and Bading 2010). Previous research showed that a strong CREB dephosphorylation is observed after the overactivation of NMDA receptors (Riccio and
Ginty 2002). It is worth noting that in the present study, we found memantine could
effectively alleviate excessive QA-induced neurite lesions. Previous studies indicated
that memantine is an NMDA receptor antagonist, but the affinity of its inhibition is not
as high as traditional antagonists (Liu, Xu et al. 2017). Xia and his colleague
demonstrated that memantine mainly inhibits the function of extrasynaptic NMDA
receptors, while it has little effect on synaptic ones (Xia, Chen et al. 2010). Previous
studies demonstrate that stimulation of synaptic NMDA receptors leads to the
activation of CREB, which can then initiate several survival genes (such as BDNF) and
suppress death genes. However, instead of activating CREB, the activation of
extrasynaptic NMDA receptors shuts off CREB, leading to the opposite effect
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(Hardingham and Bading 2010). In pathological conditions, extrasynaptic NMDA
receptors are overactivated (Gladding and Raymond 2011). These receptors can initiate
the pro-death signalling pathways and induce cell death. Therefore, this NR2B-CREBBDNF pathway could explain this QA-induced cell death. The potential mechanism
implication is shown in Fig 2.8.

Fig. 2.8 Summary of the results and potential mechanistic implications. QA caused the
activation of NMDA receptors. This activation inhibited CREB phosphorylation, thus
decreasing the BDNF expression in SH-SY5Y cells. CREB, cAMP response elementbinding protein; BDNF, brain-derived neurotrophic factor.
Overall, this study demonstrates that excessive QA causes neurite lesions in SH-SY5Y
cells. A decrease in the expression of pCREB and BDNF reveals a possible signalling
pathway that QA works on. The blockade effect of MK-801 and ifenprodil suggests the
involvement of NMDA receptors, especially NR2B receptors. Memantine and NR2B
siRNA prevented pCREB and BDNF reduction further confirming the involvement of
this NR2B-CREB-BNDF pathway.
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Chapter Three
Reciprocal regulation between NR2B and D2R in neurite
lesions
3.1

Abstract

Dopamine D2 receptors (D2R) were shown to affect NR2B-mediated signalling, which
is relevant to the maintenance of neurite integrity, but the mechanism behind this effect
is still unclear. Therefore, investigating the effect between D2R and NR2B in neurite
growth regulation is important for the therapy of neurodegenerative diseases. To this
end, this study used quantitative cell imaging, western blot assays, and interaction
techniques to show that both the overexpression of NR2B and inhibition of D2R caused
neurite lesions. In addition, neurite lesions induced by NR2B overstimulation caused
the inhibition of D2R. Conversely, D2R hypofunction also led to NR2B hyperfunction
and neurite impairment. Furthermore, using the fluorescence resonance energy transfer
(FRET), I found the NR2B-D2R interaction was enhanced by D2R hyperactivity. In
conclusion, this study uncovers that NR2B hyperactivity induced by D2R hypoactivity,
or vice versa, may induce additional effects causing neurite lesions. Therefore, a
balanced regulation between D2R and NR2B may be an important strategy for new
drug development in the treatment of severe mental diseases.
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3.2

Introduction

In the CNS, NMDARs are a major group of glutamate-dependent ion channels at
excitatory synapses in neurons. A functional NR2B receptor contains 4 subunits: two
NR1 subunits and two NR2B subunits (Sanz-Clemente, Nicoll et al. 2013). The
extracellular part contains a ligand-binding domain, which can bind to its ligands or
agonists (Paoletti and Neyton 2007). Once the ligands are bound, the intracellular
signalling pathways of NR2B can be initiated (Ross, Margolis et al. 2006). For example,
binding with glutamate can open the ion channel of NR2B, leading to a calcium influx.
The intracellular CaMK II can detect the calcium alternation and bind to the C-terminal
of NR2B (Sanz-Clemente, Gray et al. 2013), which initiates several neurite growthrelated genes for transcription in the nucleus (Qiu, Li et al. 2011, Fan, Jin et al. 2014).
NR2B contains several important phosphorylation sites, which are responsible for the
NR2B activity or distribution. For example, NR2B has several serine/threonine
phosphorylation sites, including S1303, S1323, and S1480 in the C terminal. Among
them, S1303 plays a key role in the NR2B-mediated neurite growth and neuronal
plasticity (Chen and Roche 2007, Qiu, Li et al. 2011). The S1303 site was shown to be
an important position for CaMK II binding (Chen and Roche 2007). Another wellknown phosphorylation site of NR2B is Y1472. Upregulating the phosphorylation of
Y1472 strongly inhibits the endocytosis effect of NR2B (Nakazawa, Komai et al. 2001,
Roche, Standley et al. 2001). Therefore, NR2B can initiate its downstream signalling
pathways when it is stable in the membrane.
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D2R is a seven-transmembrane domain G-protein coupled receptor. D2R has two forms:
D2R short form (D2R short) and D2R long-form (D2R long) (Vallone, Picetti et al.
2000). According to Liu et al., the long-form can form a complex with NR2B and
regulate protein expression in the post-synaptic area (Liu, Chu et al. 2006). D2R is also
a key target for psychiatric disorders medications. In bipolar disorders, dopamine
receptors are also important targets. Mania and depression are two important symptoms
of bipolar disorders, which are related to the increase and decrease of dopaminergic
function, respectively (Cousins, Butts et al. 2009). Furthermore, dopamine transporter
and D2R expression are reduced in mental illnesses during aging.
Both D2R and NR2B were shown to be dysfunctional in mental diseases. For example,
in AD, NR2B was found to be overactivated in the striatum, while D2R was found to
be reduced (Paoletti, Bellone et al. 2013, Martorana and Koch 2014). On the other hand,
a reduced NR2B activity was found in schizophrenia patients (Albert and Wood 2012,
Geddes, Huang et al. 2014), while D2R activity was found to be overstimulated in most
cases (Zakzanis and Hansen 1998, Howes and Kapur 2009). A dopamine-glutamate
interaction may exist in the brain, but the exact mechanism still needs further
investigation.
In the present study, I investigated the neuronal status under NR2B hyperactivity or
D2R hypoactivity. On the one hand, the addition of NR2B plasmid affected D2R
downstream signaling pathway. On the other hand, D2R siRNA also affected NR2B
signaling pathway. Furthermore, I found that D2R and NR2B had physical interaction,
which is critical for psychiatric disease research.
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3.3
3.3.1

Methods and materials
Antibodies and chemicals

Quinpirole hydrochloride (Sigma Aldrich, St Louis, Missouri, USA), anti-GSK3α/β
(1:1,000; Cell Signaling Technology, Danvers, USA), anti-phospho-GSK3β (Ser9)
(1:1000; Cell Signaling Technology), anti-β-actin (1:5000; Millipore, Bedford, USA),
anti-D2R (1:400, Santa Cruz Biotechnology, CA, USA), anti-NR2B (1:1000, ab28373,
Abcam), anti-phospho-NR2B Tyr1472 (1:1000, Cell Signaling Technology, Danvers,
USA), anti-phospho-NR2B-S1303 (1:1000, ab81271, Abcam), Alexa Fluor 488conjugated goat anti-mouse IgG secondary antibody (1:400; Invitrogen) and Alexa
Fluor 568-conjugated goat anti-rabbit IgG secondary antibody (1:400; Invitrogen).
NR2B plasmid and D2R siRNA were synthesized and purchased from GenScript
(GenScript, Hong Kong Ltd), and dissolved in ultrapure water to reach a stock
concentration of 10 mM.
3.3.2

Transfection

Neuroblastoma SH-SY5Y cells were grown in DMEM/F12 (Life Technologies,
Carlsbad, USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillinstreptomycin (Thermo Fisher, Waltham, USA) in 5% CO2 incubator at 37 °C. Cells
were cultured in T75/T25 flasks for 3-5 days to reach 70% confluence. Cells were then
either sub-cultured for future use or plated for experiments. 10 μM retinoic acid (RA)
was used to induce differentiation of SH-SY5Y cells. For differentiation experiments,
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SH-SY5Y cells were differentiated using DMEM/F12 with 1% of FBS while
supplemented with 10 μM all-trans-RA.
The NR2B plasmid was synthesized by GenScript (GenScript, Hong Kong Ltd) and
sub-cloned into the pcDNA3 vector. The D2R siRNA was synthesized by RiboBio
(RiboBio, Guangzhou Ltd). Transfection was performed using the Lipofectamine 2000
reagent (Life Technologies) following the manufacturer’s instructions. The neurites
were measured immediately after transfection. After 6 h of transfection, the medium
was changed to DMEM/F12 containing 1% FBS with 1 mM RA. The neurites were
continually measured for 18 h.
3.3.3

Cell culture

Primary striatal neurons are from the brain tissues of PN0 mice. All experimental
procedures have been approved by the Animal Ethics Committee, University of
Wollongong, Australia. Briefly, the striatum was collected from the pup brain and
dissociated striatal neurons were seeded at a density of 2.5 × 105 cells/cm2, onto polyD-Lysine precoated 24-well plates, containing neurobasal media (NBM) supplemented
with B27. 5-Fluoro-2′-deoxyuridine (5-FDU) is used to prevent the growth of nonneuronal cells including astrocytes and microglia. Cells were cultured in a humidified
CO2 incubator at 37 ̊C. The culture medium was changed every 2-3 days. Primary cells
can be used for experiments after 7-10 days in vitro.
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3.3.4

Immunocytochemistry

After 7-10 days culture, the cells were observed to be approximately 70% confluence
on glass coverslips, and specific treatment was performed 30 min before fixing them in
4% paraformaldehyde. Then, fixed cells were washed in PBS twice and permeabilized
with 0.3% Triton X-100 in PBS for another 10 min. After that, 5% normal goat serum
was used to block the coverslips for 1-2 h. A primary antibody for the specific receptor
was then used in 1% goat serum in PBS at room temperature overnight, followed by a
secondary antibody incubation for another 2 h at room temperature. Finally, the
fluorescence of the cells was observed using a 40× or 63× oil immersion objective on
a DMI6500B confocal microscope (Leica, Mannheim, Germany).
3.3.5

Western blot

The whole procedure of western blot was performed following the protocol in our lab.
Briefly, tissue samples were separated by SDS-polyacrylamide gel electrophoresis
using pre-cast 10% Tris-Glycine gels (Invitrogen) and then electroblotted onto a
polyvinylidene difluoride membrane (PVDF) for 2 h and 15 m. The membranes were
blocked with Tris-buffered saline using Tween-20 (TBS-T) containing 5% milk at room
temperature for 1 h and then incubated with the primary antibodies of GSK-3β, p GSK3β, pCaMK II and pNR2B S1303 for 12 h at 4 °C. Then, the membranes were washed
in TBS-Tween and incubated at room temperature for 2 h with species-specific
secondary antibodies. The detection of proteins conjugated with antibodies was
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performed using chemiluminescence. The blots are exposed to film, and signal intensity
was quantified relative to the loading control β-actin, using the ImageJ software.
3.3.6

Fluorescence resonance energy transfer (FRET)

For D2R-NR2B interaction, anti-D2R-Alexa Fluor 488 was used as a donor dipole and
anti-NR2B-Alexa Fluor 568 was used as an acceptor dipole. 488 nm is set as the
excitation wavelength and 603 nm is set as the emission wavelength. Primary cells were
analysed by using the Leica application wizard for FRET.
3.3.7

Statistical analysis

Statistical analysis was performed using the SPSS program (version 21; Chicago, IL,
United States) and the GraphPad Prism 7 software (GraphPad Software, Inc., La Jolla,
CA, USA). One-way analysis of variance (ANOVA) was used respectively for doseresponse and time-response curves. Student t-test was used when only two groups were
compared. ANOVA was used when analyzing three or more groups. Data were
expressed as mean ± SEM, and p < 0.05 was considered statistically significant.
3.3.8
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3.4
3.4.1

Results
NR2B hyperactivity increased GSK-3β Ser9 phosphorylation and induced
neurite lesions

To confirm whether NR2B hyperactivity can be affected by D2R activity, I firstly
transfected NR2B plasmid into SH-SY5Y neuronal cells to determine whether an
elevated NR2B expression could affect neurite growth. Results showed that cells
transfected with NR2B plasmids showed significant neurite lesions in 24h. It confirmed
that NR2B overexpression caused neurite lesions in SH-SY5Y cells. I then used D2R
agonist quinpirole to prevent this NR2B plasmid-induced neurite lesions. Results
showed that 10 μM quinpirole effectively reduced NR2B plasmid-induced neurite
lesions (Fig 3.1 A-C). Next, I used Western blot to examine D2R and its downstream
protein GSK-3β to confirm that overexpression of NR2B affects neurite growth via
D2R and its downstream signalling pathway. I first tested if NR2B plasmid was
successfully expressed in SH-SY5Y cells and whether such expression was continuous.
Results showed that massive NR2B was expressed in SH-SY5Y cells in 24h. This
system was therefore confirmed successful (Fig 3.1 E). I later detected D2R and its
downstream protein GSK3β and found that although the D2R expression level was
unchanged, phosphorylation of GSK3β Ser9 was significantly changed (Fig 3.1 F).
These results strongly suggested that D2R-NR2B interaction might be involved in
neurite lesions mediated by NR2B overexpression.
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Fig 3.1 D2R agonist quinpirole prevents neurite lesions induced by NR2B
overexpression. (A and B) Representative images of transfected SH-SY5Y cells (Scale
bar represents 50 μm). Cells transfected with NR2B plasmids (1 μg/mL) were shown
in A; Cells transfected with NR2B plasmids (1 μg/mL) and quinpirole (10 μM) were
shown in B (n > 80 cells for each condition). (C) Quantification of neurite length in A
and B. (D) Representative Western blot of NR2B, D2R, and GSK-3β Ser9
phosphorylation. Cells were transfected with NR2B plasmids (1 μg/mL) for 24h. (E)
NR2B expression levels were higher after 24h transfection. (F) GSK-3β Ser9
phosphorylation expression levels were higher after 24h transfection. Data are
presented as means ± S.D. * p < 0.05; ** p < 0.01, *** p < 0.001 vs. control group.
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3.4.2

D2R hypoactivity increased pGSK3B expression and neurite lesions

My hypothesis was that D2R and NR2B affect each other in the neuronal membrane.
Since I found that NR2B overexpression could affect D2R activity, it was necessary to
know whether direct inhibition of D2R affected NR2B activity. I thus investigated if
D2R hypofunction also affected NR2B through D2R-NR2B interaction. 5 pmol D2R
siRNA was transfected into SH-SY5Y cells to inhibit D2R expression. Neurite length
per cell body was determined to evaluate neurite morphology. Results showed that
neurite lesions were observed in cells transfected with D2R siRNA (Fig 3.2A) and
confirmed that D2R hypofunction affected neurite length in SH-SY5Y cells.
Next, I examined the expression level of D2R and its downstream pGSK-3β Ser9 to
determine if the transfection process was successful. Results indicated that the D2R
expression level was low (Fig 3.2D), while GSK-3β Ser9 phosphorylation was higher
than the control group (Fig 3.2E). Since D2R siRNA is used to interrupt the
transcription process of D2R, it is reasonable to detect a decrease in D2R expression.
Meanwhile, the increase in GSK-3β Ser9 phosphorylation suggested that D2R function
was also inhibited due to the transfection. I then investigated if transfection of D2R
siRNA could affect NR2B by detecting the expression level NR2B and two
phosphorylation sites, S1303 and Y1472. Results showed interestingly that both NR2B
and its Y1472 phosphorylation were increased after D2R siRNA treatment (Fig 3.2H,
I). NR2B S1303 phosphorylation also showed a trend of increase that was not
significant. Moreover, I detected CaMK II, a direct downstream protein of NR2B, to
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evaluate the effect of D2R siRNA on NR2B activity (Fig 3.2J). Results showed that
CaMK II expression was also increased after D2R siRNA treatment, suggesting that
D2R siRNA also regulated NR2B downstream signalling. Furthermore, I used the
immunofluorescence technique to detect NR2B expression in primary striatal neurons
and my results revealed NR2B level was increased after adding haloperidol, a D2R
antagonist (Fig 3.2K, L). It is therefore suggested that D2R inhibition could regulate
NR2B expression and activity.
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Fig 3.2 Reduced D2R activity induces neurite lesions in SH-SY5Y. (A and B)
Representative images of transfected SH-SY5Y cells (Scale bar represents 50 μm).
Control cells were shown in A; Cells with D2R siRNA were shown in B (n > 80 cells
for each condition). (C) Quantification of neurite length in A and B. (D) Representative
western blot of D2R and GSK-3β Ser9 phosphorylation sites. Cells were transfected
with D2R siRNA (5pmol) for 24h. (E) D2R expression levels were lower after 24h
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transfection, (F) GSK-3β Ser9 phosphorylation expression levels were higher after 24h
transfection. (G) Representative western blot of NR2B, NR2B Y1472 phosphorylation,
and CaMK II. Cells were transfected with D2R siRNA (5pmol) for 24h. (H) NR2B
expression level after 24 h. (I) NR2B pY1472 expression level was higher after 24 h.
(J) CaMK II expression was higher after 24 h. (K) Primary striatal neurons were treated
with 10 μM quinpirole or 10 μM haloperidol for 24 h (Scale bar represents 30 μm). (L)
Quantification of immunofluorescence signals in h. Data are presented as means ± S.D.
* p < 0.05, *** p < 0.001 vs. control group.
3.4.3

D2R agonist quinpirole increases direct protein-protein interaction
between D2R and NR2B

To demonstrate that D2R and NR2B have direct physical interaction, I used the FRET
technique to confirm that D2R and NR2B can form a complex (Fig 3.3). In this study,
quinpirole (10 μM) was used as a D2R agonist. Results showed that D2R and NR2B
can form a complex on the membrane and the FRET signal was strengthened when
D2R was activated by quinpirole.
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Fig 3.3 D2R agonist quinpirole increases D2R-NR2B interaction. (A) Representative
images of D2R and NR2B distribution in primary striatal neurons. Confocal FRET
analysis was used to detect the interaction (Scale bar represents 30 μm). (B)
Quantification of FRET signal in a. n > 20 cells per group. Data are means ± S.D. ***p
< 0.001 vs. control group.
3.5

Discussion

My results have revealed a direct reciprocal interaction between D2R and NR2B at the
receptor level. NR2B hyperactivity caused an upregulation of GSK-3β at the same time
D2R was inhibited. On the other hand, D2R hypoactivity directly increased Y1472
phosphorylation and expression of NR2B expression, suggesting that NR2B activity
can be regulated by D2R. Furthermore, FRET results suggested that NR2B and D2R
formed a complex in the cell membrane.
NR2B is known as a group of ionotropic glutamate receptors, which are found
responsible for neurite growth and synaptic plasticity (Paoletti and Neyton 2007). In
the present study, I have established in this study an overexpressed NR2B model so the
cells could produce more NR2B. My results confirmed that more NR2B was expressed
in cells after 24h in connection with serious neurite lesions among RA-induced cells.
This is consistent with previous studies. It is known that NR2B hyperactivity can cause
neurite lesions and neuron death (Ronicke, Mikhaylova et al. 2011) due to upregulation
of Ca2+ influx. This initially causes synaptic dysfunction and synaptotoxicity, followed
up by neurite lesions and neuron loss (Matsumura, Kunori et al. 2010). Moreover, I
found that the addition of NR2B plasmid increased GSK-3β Ser9 in SH-SY5Y cells,
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suggesting an inhibition effect of GSK-3β. The addition of quinpirole protected cells
from neurite lesions, which suggested that D2R activation can protect from NR2B
overactivation induced neuronal damage.
On the other hand, a 40% reduction of D2R in SH-SY5Y cells caused serious neurite
lesions due to the transfection of D2R siRNA. This confirmed normal D2R expression
level was necessary for neuronal cells. It is well known that dopamine D2 receptors are
key targets for the treatment of psychiatric disorders. In mental illnesses during aging,
it is found that dopamine transporter and D2R expression are reduced in the brain (Jia,
Zhao et al. 2013, Martorana and Koch 2014). Atrophy is also found in some parts of
the brain due to D2R reduction in late-stage patients (Martorana and Koch 2014). Here
I reported that D2R also affected the phosphorylation of NR2B. A previous paper
reported that D2R interacts with S1303 of NR2B receptors (Fan, Jin et al. 2014). I
found that the Y1472 of the NR2B receptor is also affected by D2R inhibition. The
Y1472 of NR2B receptor is known to regulate the surface expression and endocytosis
of NR2B receptors (Wu, Chen et al. 2017), therefore my result suggests that the
inhibition of D2R also affects NR2B receptors. I also found that the expression of
CaMK II, a direct downstream protein of NR2B that controls calcium influx, increased
due to D2R inhibition. Therefore, D2R siRNA might also increase NR2B activity. As
hyper-activated NMDARs are well known to lead to rapid neuronal death due to
excitotoxicity (Liu, Wong et al. 2007, Hardingham and Bading 2010), this study
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suggested that the neurite lesions caused by D2R inhibition might also be due to NR2B
hyperactivity.
Both NR2B and D2R are known to form complexes (Liu, Chu et al. 2006, Jia, Zhao et
al. 2013). According to Liu et al., the NR2B S1303 site was essential for binding with
D2R. Meanwhile, the calcium influx of NR2B could also be blocked due to the D2R
agonist cocaine. Moreover, NR2B S1303 site is a key position for both D2R and CaMK
II binding. It was thus suggested that increased D2R-NR2B complex formation
prevents NR2B from binding to other proteins such as CaMK II (Liu, Chu et al. 2006).
In the present study, FRET results confirmed that a direct D2R-NR2B interaction can
be regulated by D2R activity. Therefore, my results support that D2R-NR2B has direct
interaction. The relation between NR2B and D2R is summarized in Fig 3.4.

Fig 3.4 A direct reciprocal interaction between D2R and NR2B at the receptor level.
The carboxyl tail of the NR2B subunit binds to the 225-234 region of D2R on the
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membrane. NR2B hyperactivation will inhibit the activity of D2R. In contrast, the
inhibition of D2R can promote NR2B and its calcium-related signalling pathway.
In summary, this study demonstrates that both NR2B overstimulation and D2R
inhibition caused neurite lesions. However, NR2B and D2R form complexes and
interact with each other. Therefore, in mental diseases then, NR2B or D2R should not
be considered separately as their interaction and balance could be more important
factors.
3.6

Significance

My study has shown that both hyperactivity of NR2B and hypoactivity of D2R can lead
to neurite lesions and their imbalance can play an important role in neurodegenerative
diseases. AD is a chronic, progressive neurodegenerative disease (Mattson 2000), the
exact aetiology of which is still not completely understood though severe excitotoxicity
induced by NMDAR hyperactivity is always found in its patients (Fuentealba, Farias et
al. 2004). Many compounds that can stimulate NMDAR are of high interest in recent
studies. QA is an endogenous metabolite of the kynurenine pathway (KP) and could
activate NMDA, especially NR2A and NR2B, in neurons (Guillemin 2012). Studies
have shown that excessive QA caused neurotoxicity in neurons (Perez-De La Cruz,
Carrillo-Mora et al. 2012). Meanwhile, QA is found to accumulate in plaques of senile
AD patients (Giulian, Haverkamp et al. 1995), thus suggesting that NR2B is responsible
for the excitotoxicity of NMDAR that causes neurodegeneration in AD patients.
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Chapter Four
QA-induced ROS is prevented by ifenprodil and olanzapine
4.1

Abstract

Excessive QA induces neurite lesions in the brain. Previous studies demonstrated
excessive QA can induce overactivation of NMDA receptors and reactive oxygen
species (ROS) formation. However, the exact mechanism was not clear yet. This study
investigated the effect of QA on ROS and autophagy. Excessive QA was found to cause
a significant ROS increase in neuronal cells. The increase of p62 and LC3b-II caused
by QA suggested that autophagy completion was impaired. Both NR2B antagonist
ifenprodil and antipsychotic drug olanzapine prevented QA-induced ROS. A low dose
of olanzapine decreased ROS, while a high dose of olanzapine showed no effect on
excessive QA-induced neurite lesions. Moreover, low-dose olanzapine reduced p62 but
not LC3b-II in SH-SY5Y cells, which suggested autophagy was restored by olanzapine.
Taken together, these results suggested excessive QA increased ROS and impaired
autophagy in neuronal cells. Ifenprodil and olanzapine prevented this QA-induced ROS
production and autophagy impairment.
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4.2

Introduction

Neurodegenerative disorders, such as Alzheimer’s, are multifactorial ones that induce
slow and progressive loss of neuronal cells. However, the exact mechanism for this is
still largely unknown. Studies have shown that QA is abnormally high in patients with
neurodegenerative diseases (Lugo-Huitron, Ugalde Muniz et al. 2013, Maddison and
Giorgini 2015). QA is an endogenous tryptophan metabolite of the kynurenine pathway.
Previous studies have indicated that QA is an NMDA receptor agonist which increases
calcium influx, followed by excitotoxicity and impairment (Tavares, Tasca et al. 2002,
Braidy, Grant et al. 2009). Since overactivation of NMDA receptors causes
neurotoxicity and leads to neuronal death, QA is always considered a neurotoxin that
contributes to the pathology of many neurodegenerative diseases (Ting, Brew et al.
2009, Schwarcz, Guidetti et al. 2010). Indeed, QA concentration is abnormal in
neurological disorders such as Alzheimer’s, schizophrenia, HIV-associated dementia
(HAD), etc. (Ting, Brew et al. 2009, Kandanearatchi and Brew 2012, Kegel, Bhat et al.
2014). However, activating NMDA receptors and increasing calcium influx are not the
only ways that QA causes neuronal damage. In recent years, more studies have focused
on QA-induced reactive oxygen species (ROS) formation and oxidative damage to both
cells and mitochondria (Perez-De La Cruz, Carrillo-Mora et al. 2012, Lugo-Huitron,
Ugalde Muniz et al. 2013). The brain is vulnerable to ROS and the ROS damage can
thus develop neurodegenerative diseases (Kim, Kim et al. 2015). Previous studies
already indicated that QA can induce free hydroxyl radical (OH) formation,
lipoperoxidation, and superoxide anion radical in the brain (Iwahashi, Kawamori et al.
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1999, Rodriguez-Martinez, Camacho et al. 2000). Meanwhile, this mechanism is
considered independent of that of activating NMDA receptors and increasing calcium
influx (Perez-De La Cruz, Carrillo-Mora et al. 2012).
Autophagy is a process that maintains cellular homeostasis. Its main functions include
self-degradation, removing unnecessary proteins, eliminating intracellular pathogens,
etc. (Glick, Barth et al. 2010). Studies have demonstrated that ROS can activate
autophagy (Scherz-Shouval and Elazar 2011, Filomeni, De Zio et al. 2015), an
interesting fact because ROS can cause a series of neuronal damage and cell death in
the CNS (Wang and Michaelis 2010, Salim 2017). The downstream process of
autophagy can however clear aged or unnecessary intracellular contents such as
damaged mitochondria and aggregated proteins (Kulkarni, Chen et al. 2018).
Autophagy is therefore considered a compensating mechanism of ROS (Filomeni, De
Zio et al. 2015).
Many antipsychotic drugs, such as haloperidol, clozapine, and olanzapine, are known
to be related to ROS and the autophagy process (Park, Chung et al. 2012, Vucicevic,
Misirkic-Marjanovic et al. 2014). Although most antipsychotic drugs are considered
dopamine D2 receptor antagonists, their mechanisms for ROS and autophagy are
different (Vucicevic, Misirkic-Marjanovic et al. 2018). For example, the autophagy
process was considered impaired due to the addition of antipsychotic drugs. Vucicevic
and his colleagues have found a high dose of olanzapine causes both the rising in ROS
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production and autophagy. The cell survival rate is even lower when an autophagy
inhibitor is added (Vucicevic, Misirkic-Marjanovic et al. 2014).
In the present study, I showed that increased QA caused ROS formation and autophagy
impairment. The NR2B receptor antagonist ifenprodil decreases ROS production
caused by excessive QA. Low-dose olanzapine also alleviates QA-induced ROS and
neurite impairment. In addition, low-dose olanzapine prevented excessive QA-induced
autophagy impairment.
4.3
4.3.1

Methods and materials
Antibodies and chemicals

Quinolinic acid (Cayman, 14941), MK-801 (Sigma Aldrich, St Louis, Missouri, USA),
ifenprodil (Sigma Aldrich, St Louis, Missouri, USA), memantine (Cayman, 14184),
olanzapine (Cayman, 11937), anti-LC3b (1:1,000; Cell Signaling Technology, Danvers,
USA), anti-p62 (1:1000; Cell Signaling Technology), anti-β-actin (1:5000; Millipore,
Bedford, USA), anti-NR2B (1:1000, ab28373, Abcam), Alexa Fluor 488-conjugated
goat anti-mouse IgG secondary antibody (1:400; Invitrogen) and Alexa Fluor 568conjugated goat anti-rabbit IgG secondary antibody (1:400; Invitrogen).
4.3.2

Cell culture

Neuroblastoma SH-SY5Y cells were grown in DMEM/F12 (Life Technologies,
Carlsbad, USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillinstreptomycin (Thermo Fisher, Waltham, USA) in 5% CO2 incubator at 37 °C. Cells
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were cultured in T75/T25 flasks for 3-5 days to reach 70% confluence. Cells were then
either sub-cultured for future use or plated for experiments. 10 μM retinoic acid (RA)
was used to induce differentiation of SH-SY5Y cells. For differentiation experiments,
SH-SY5Y cells were differentiated using DMEM/F12 with 1% of FBS while
supplemented with 10 μM all-trans-RA.
4.3.3

Cell viability assay

Neuroblastoma SH-SY5Y cells were seeded in a 96-well plate. Cells were treated with
compounds or drugs for 24 h before measurement. Cell viability was measured by the
MTT viability assay. Cells were treated with MTT dye for 10 mins at 37°C before
reading. Then plates were put in a plate reader and measured at 570 nm to get
fluorescence intensity.
4.3.4

Neurite outgrowth/extension assay

To study neurite growth of control and treated SH-SY5Y cells, cells were plated in 96well plates at a density of 2*104 cells/mL. After treatment with compounds of interest,
cells were put in the incucyte machine. Images were taken every 2-6 hours from the
beginning. The neurites were analysed using Neurotrack software. Considering that cell
density cannot be even in each well, Neurite length per cell body cluster was used to
reflect the extension level of neurites.

98

4.3.5

Western Blot

The Western blot protocol in our lab was followed. Tissue samples were separated by
SDS-polyacrylamide gel electrophoresis using pre-cast 10% Tris-Glycine gels
(Invitrogen) and then electroblotted onto a polyvinylidene difluoride membrane (PVDF)
for 2 hours and 15 minutes. Membranes were blocked with Tris-buffered saline with
Tween-20 (TBS-T) containing 5% milk at room temperature for an hour. These were
then incubated with primary antibodies at 4°C to LC3b-II and p62 for 12 hours
(overnight). Membranes were then washed in TBS-Tween and incubated at room
temperature for 2 hours with species-specific secondary antibodies. Detection of
proteins conjugated with antibodies was performed with chemiluminescence. Blots
were exposed to film, and signal intensity was quantified relative to the loading control
β-actin, using Image J software.
4.3.6

ROS production

The intracellular ROS and mitochondrial ROS were measured by flow cytometry, using
a BD Accuri™ C6 Plus Flow Cytometer (BD Biosciences). The cell-permeant 2',7'dichlorodihydrofluorescein diacetate (H2DCFDA) (Thermofisher Scientific, D399)
was used to measure the intracellular ROS, and MitoSOX Red Mitochondrial
Superoxide Indicator (ThermoFisher Scientific, M36008) was used to measure
mitochondrial ROS. After 15 min treatment with H2DCFDA, cells were washed in
phosphate-buffered saline (PBS). Cells were then mixed and collected in a 1.5 mL
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Eppendorf tube. FITC (fluorescein isothiocyanate), corresponding to intracellular ROS
levels, was determined by flow cytometry.
4.3.7

Acridine orange (AO) staining

pH-sensitive dye acridine orange (AO) (Sigma-Aldrich, 318337) was used to determine
the number of intracellular acidic vesicles. BD Accuri™ C6 Plus Flow Cytometer (BD
Biosciences) was used for the measurement. Flow cytometric analysis was measured as
previously described.
4.3.8

Statistical analysis

Statistical analysis was performed using the SPSS program (version 21; Chicago, IL,
United States). One-way analysis of variance (ANOVA) was used respectively for
dose-response and time-response curves. Student t-test was used when only two groups
were compared. Data were expressed as mean ± SEM, and p < 0.05 was considered
statistically significant.
4.4
4.4.1

Results
Excessive quinolinic acid induced ROS production

ROS is a group of highly reactive chemical molecules and plays important role in cell
homeostasis. Redundant ROS causes irreversible damage to cells and their organelles,
especially mitochondria. I investigated whether QA-induced neurite lesions are caused
by oxidative stress by staining the ROS in SH-SY5Y cells and analyzing the results
using flow cytometry. Based on my previous study and preliminary results, I decided
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to add up to 100 µM QA to treat the cells. At 100 µM, QA significantly caused neurite
lesions but was non-lethal to the cells. I then determined the effect of QA without
considering the change caused by cell death. Flow cytometric analysis showed that cells
treated with 1-100 µM QA could significantly increase both total ROS and
mitochondrial ROS production (Fig 4.1). These results suggested that QA-induced ROS
production in SH-SY5Y cells. Since 100 μM QA showed the most significant neurite
reduction while only a small percentage of cell death was observed in the MTT assay,
I decided to use 100 μM QA for the following ROS experiments.
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Fig 4.1 QA induced ROS generation. (A) Representative micrograph of 50 μM QAinduced total ROS (green) and mitochondrial ROS (red). (B, C) Histogram of total ROS
and mitochondrial ROS (n=20). (D, E) SH-SY5Y cells were incubated with various
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concentrations of QA, and DCFDA was assessed by flow cytometry. (F, G) SH-SY5Y
cells were incubated with various concentrations of QA, and the mitochondrial ROS
production was examined by flow cytometry. Results are presented as the ratio of
control (untreated group). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control group
4.4.2

Excessive quinolinic acid affected autophagy

Previous research has demonstrated ROS increase was associated with the activation of
autophagy (Scherz-Shouval and Elazar 2011), thus I next assessed whether excessive
QA affected autophagy. Cells incubated with 100 µM QA were stained with AO to
determine the autophagy process due to proportions of, respectively, green and red
fluorescence. Flow cytometry results confirmed that 100 μM QA activated the
autophagy process in SH-SY5Y cells. I likewise measured autophagy-associated
proteins p62 and LC3b-II in SH-SY5Y cells. Western blot results demonstrated that
QA increased the conversion of LC3b-I to LC3b-II which suggested the activation of
the autophagy process. p62 did not show a significant change but a rising trend was
observed after treatment of 100 μM QA (Fig 4.2). Taken together, these data
demonstrated that excessive QA affected autophagy in SH-SY5Y cells.
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Fig 4.2 QA affects autophagy in SH-SY5Y cells. (A) SH-SY5Y cells incubated w/o
QA were assessed by flow cytometry analysis of autophagy marker AO3/AO1 (B)
Quantification of AO3/AO1 (C, D) The levels of proteins involved in autophagy
regulation were determined by western blot (n=6). Data are presented as means ± S.D.
**p < 0.01 vs. untreated group.
4.4.3

Quinolinic acid-induced ROS was prevented by NR2B antagonist
ifenprodil

Previous papers have indicated that QA-induced ROS could be affected when NMDA
receptors were inhibited (Santamaria, Galvan-Arzate et al. 2001). It is thus important
to know whether NMDA receptor antagonists can also affect QA-induced ROS. Three
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different NMDA receptor antagonists were chosen. Memantine is a well-known
NMDA receptor antagonist for the treatment of medium to severe Alzheimer’s disease
(Johnson and Kotermanski 2006). Ifenprodil is a strong antagonist of the NR2B
receptor. MK-801 is an NMDA receptor blocker. Results in Fig 4.3 showed that both
ifenprodil and MK-801 effectively prevented QA-induced ROS in SH-SY5Y cells. The
effect of ifenprodil and MK-801 were also dose-dependent. Memantine (up to 10 µM)
did not show any improvement in reducing ROS production. Since ifenprodil is an
NR2B antagonist, these results suggested that NMDA receptors, especially NR2B
receptors, were involved in QA-induced ROS in SH-SY5Y cells. Meanwhile, although
memantine could not prevent QA-induced ROS, it is known to save QA-induced neurite
lesions in SH-SY5Y cells. This suggested that inhibition of NR2B receptors prevented
QA-induced ROS production.
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Fig 4.3 Intracellular ROS is decreased by using NMDA antagonists ifenprodil and MK801. SH-SY5Y cells are treated with 100 μM QA to induce ROS generation. (A) DoseResponse curve of ifenprodil and QA in SH-SY5Y cells. (B) Flow cytometry analysis
for 10 μM ifenprodil. Results are presented as ratios of control (untreated group). (C)
Plots of fluorescence intensities of DCFDA dye in QA treated cells (red) or ifenprodil
+ QA treated cells (blue). (D) Dose-Response curve of MK-801 and QA in SH-SY5Y
cells. (E) Flow cytometry analysis for 10 μM MK-801. Results are presented as ratios
of control (untreated group). (F) Plots of fluorescence intensities of DCFDA dye in QA
treated cells (red) or MK-801 + QA treated cells (blue). Data are presented as means ±
S.D. ***p < 0.001 versus untreated group; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. QA
group.

Fig 4.4 Intracellular ROS is not decreased by using 10 μM memantine. SH-SY5Y cells
are treated with 100 μM QA to induce ROS generation. (A) Dose-Response curve of
memantine and QA in SH-SY5Y cells. (B) Flow cytometry analysis for 10 μM
memantine. Results are presented as ratios of control (untreated group). (C) Plots of
fluorescence intensities of DCFDA dye in QA treated cells (red) or mem + QA treated
cells (blue). Data are presented as means ± S.D. **p < 0.01 vs. untreated group.
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To investigate if memantine can affect the autophagy process in SH-SY5Y cells, p62
and LC3b-II expression were measured. Results in Fig 4.5 showed that memantine had
no significant effect on the autophagy process.

Fig 4.5 Memantine did not affect autophagy. (A) Representative western blots showing
protein expression of LC3b-II under 1 μM memantine treatment. (B) Bar charts of the
analysis of LC3b-II protein expression. (C) Representative western blots showing
protein expression of p62 under 1 μM memantine treatment. (D) Bar charts of the
analysis of p62 protein expression. Data are presented as means ± S.D. *p < 0.05 vs.
untreated group.
4.4.4

Excessive quinolinic acid-induced neurite lesions were prevented by a low
dose olanzapine

Olanzapine is an antipsychotic drug that is widely used in schizophrenia as well as other
psychiatric disorders. Research papers have indicated that quinolinic acid is abnormally
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high in schizophrenia (Cathomas, Guetter et al. 2021). Therefore, to investigate whether
olanzapine could prevent QA-induced neurite lesions via ROS formation, cells were
treated with excessive QA together with/without various concentrations of olanzapine.
The control group was treated with 100 μM QA only to cause neurite lesions. Data in
Fig 4.6 showed that 1 μM olanzapine prevented neurite lesions but when the
concentration was high there was more severe neurite impairment. Meanwhile, cells
treated with 50 μM olanzapine were seen to adhere tightly to the plates with no
significant cell death observed. These results showed that olanzapine could rescue QAinduced neurite impairment in SH-SY5Y cells only at a relatively low dose.
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Fig 4.6 QA-induced neurite lesions were prevented by low-dose olanzapine. (A) Doseresponse effect of QA and olanzapine for 24h in SH-SY5Y cells. (B) Time-response
curve of QA and olanzapine in –SH-SY5Y cells. (C) Neurite length was not reduced at
1 µM olanzapine treatments in SH-SY5Y cells for 24 h (n = 3-4, run in triplicate); (D)
Representative images of cells w/o QA and olanzapine treatments in SH-SY5Y cells;
(E) Neurite length was significantly reduced at 50 µM olanzapine treatments in SHSY5Y cells for 24 together with QA (n = 3-4, run in triplicate); (F) Representative
images of cells w/o QA and 50 µM olanzapine treatments in SH-SY5Y cells. Data are
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presented as means ± S.D. ***p < 0.001 versus untreated group; #p < 0.05, ###p <
0.001 vs. QA group
4.4.5

Olanzapine did not induce neurite regeneration

Nerve injury was found in many neurodegenerative diseases. Previous studies have
shown that the addition of neurotrophins like BDNF can induce neurite elongation and
initiate the neurite regeneration process in primary cells (Leal, Afonso et al. 2015). I
used a neurite-scratch assay to examine the effect of olanzapine on improving neurite
regeneration in primary cortical neurons. The image was captured from Incucyte. I
found that olanzapine did not induce neurite regeneration significantly, although some
trend was seen at a low dose. This low-dose olanzapine showing better results than high
ones might be due to the toxic effect of olanzapine at high concentrations (Fig 4.7).
These results showed olanzapine cannot induce neurite regeneration, which indicated
that it cannot stimulate the expression of neurotrophins such as BDNF and NGF in
primary cortical neurons.
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Fig 4.7 Olanzapine did not induce neurite regeneration for primary cortical neurons. (A)
Time-response curve of QA and olanzapine in primary cortical cells. (B) Representative
images of cells w/o QA and olanzapine treatments in cortical neurons; (C) Neurite
length was not regenerated at 50 µM olanzapine treatments in primary cortical cells for
72 h (n = 3-4, run in triplicate); (D) Representative images of cells w/o QA and
olanzapine treatments in cortical cells; (E) Neurite length was not regenerated at 1µM
olanzapine treatments in primary cortical cells for 72h (n = 3-4, run in triplicate). Data
are presented as means ± S.D. ***p < 0.001 vs. control group.
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4.4.6

Quinolinic acid-induced ROS was prevented by a low dose of olanzapine

Olanzapine is known to regulate ROS and autophagy in neuronal cells. It is interesting
to see whether olanzapine could prevent ROS production induced by excessive QA.
Since either low or high dose olanzapine might cause differences in the status of SHSY5Y cells, I tested both 1 μM and 50 μM olanzapine. Results in Fig 4.8 showed that
1 μM olanzapine reduced intracellular ROS caused by excessive QA. 50 μM olanzapine,
together with 100 μM QA, did not show a significant change in ROS compared with
100 μM QA only. In addition, cells treated with 50 μM olanzapine only did not show
any increase in ROS compared to the control, meaning 50 μM olanzapine might not
cause any significant change to the ROS.

112

Fig 4.8 QA-induced ROS could be prevented by a low dose of olanzapine but not a
high dose. Intracellular ROS is affected by using 1 μM olanzapine, but not increased
by using 50 μM olanzapine. SH-SY5Y cells are treated with 100 μM QA to induce ROS
generation. (A) Flow cytometry analysis for 1 μM olanzapine. Results are presented as
ratios of control (untreated group). (B) Plots of fluorescence intensities of DCFDA dye
in QA treated cells (red) or olanzapine + QA treated cells (blue). (C) Flow cytometry
analysis for 50 μM olanzapine. Results are presented as ratios of control (untreated
group). (D) Plots of fluorescence intensities of DCFDA dye in QA treated cells (red) or
Olan + QA treated cells (blue). Data are presented as means ± S.D. *p < 0.05 vs.
untreated group; #p < 0.05 vs. QA group
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4.4.7

Quinolinic acid-induced autophagy was prevented by a low dose of
olanzapine

I next examined whether olanzapine could prevent excessive QA-induced autophagy
impairment. In an investigation of how a low dose of olanzapine rescued SH-SY5Y
cells, I detected two key proteins in the process of autophagy, p62, and LC3b-II. Results
showed that 1 μM olanzapine reduced QA-induced p62 expression in SH-SY5Y cells.
Meanwhile, a high dose of olanzapine increased p62 which caused more impairment to
the neurons (Fig 4.9). Therefore, a proper concentration of olanzapine could effectively
affect the status of neuronal cells.
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Fig 4.9 Low dose olanzapine induced the completion of autophagy. (A) Representative
western blots showing protein expression of LC3b-II under 1 μM olanzapine treatment.
(B) Bar charts of the analysis of LC3b-II protein expression. (C) Representative western
blots showing protein expression of p62 under 1 μM olanzapine treatment. (D) Bar
charts of the analysis of p62 protein expression. (E) Representative western blots
showing protein expression of LC3b-II under 50 μM olanzapine treatment. (F) Bar
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charts of the analysis of LC3b-II protein expression. (G) Representative western blots
showing protein expression of p62 under 50 μM olanzapine treatment. (H) Bar charts
of the analysis of p62 protein expression. Data are presented as means ± S.D. * p < 0.05,
**p < 0.01 vs. untreated group; ## p < 0.01, ### p < 0.001 vs. QA group.
4.5

Discussion

In this study, I found that excessive QA significantly increased ROS production and
affected the autophagy process. NR2B antagonist ifenprodil prevented this QA-induced
ROS formation suggesting the involvement of NR2B receptors. In addition, a low dose
of olanzapine also decreased ROS production and p62 in the cells, which suggests the
concentration is an important factor in the olanzapine-mediated autophagy process.
Previous studies have demonstrated that a high dose of olanzapine could induce ROS
and autophagy, accompanied by decreased cell viability (Vucicevic, MisirkicMarjanovic et al. 2014), which are similar to my result. Ljubica Vucicevic et al. have
indicated that 100 µM olanzapine induces both ROS and autophagy. Meanwhile, the
blockade of autophagy by bafilomycin decreases autophagy but also causes more cell
death. Their results suggest the protective effect of autophagy when ROS is rising.
However, I found that olanzapine could prevent QA-induced ROS and autophagy when
the concentration was decreased to about 1 µM. This is interesting because it means
that a low dose of olanzapine might be helpful for neuronal cells while the toxicity
caused by olanzapine might be due to the high dose. Xiong YJ and his colleagues have
studied the influence of olanzapine on induced neurotoxicity. They found that
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olanzapine could significantly reduce neurotoxicity in PC12 cells through the AMPKautophagy pathway (Xiong, Song et al. 2020). The concentration of olanzapine used
was 20 µM while in Vucicevic et al.’s study, the concentration was 100 µM. The dosage
used for cells might thus be an important factor for neuronal cells. Relatively low dose
olanzapine could help the completion of the autophagy process without activating ROS
significantly. Therefore, a low dose of olanzapine might be helpful to the neurons.
When the concentration of olanzapine becomes higher, it increases ROS production.
Since Vucicevic et al. have already mentioned that the blockade of autophagy will
exacerbate cell death, Part of the autophagy induced by a high concentration of
olanzapine may be initiated because of the increase in ROS.
My results showed that QA increased LC3b conversion from LC3b-I to LC3b-II in SHSY5Y cells. During the autophagy process, LC3b-II is formed by the conjugation with
LC3b-I and phosphatidyl-ethanolamine (PE). This conjugated form of LC3b-II is
involved in forming the autophagosome membrane (Mizushima 2007, Yu, Chen et al.
2018). LC3b-II/LC3b-I conversion rate is a biomarker of the autophagy process (Karim,
Kanazawa et al. 2007, Wang, Boulton et al. 2009). My study showed an increased
LC3b-II/LC3b-I ratio, suggesting that QA activated the autophagy process. It is noted
that an increased LC3b-II/LC3b-I ratio indicates an autophagy initiation but not
completion (Gimenez-Xavier, Francisco et al. 2008). Also, an increased LC3b-II could
be due to an impaired autophagosome clearance (Cui, Sun et al. 2017). Therefore, my
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present study indicates a QA-induced autophagy initiation, but not an autophagy
completion.
Moreover, the present study showed excessive QA also increased the p62 level in SHSY5Y cells. p62 is known as an autophagosome cargo protein and will be degraded in
the autophagy process (Bjorkoy, Lamark et al. 2005). The accumulation of p62
suggested the inhibition of the degradation of autolysosomes (Wu, Jin et al. 2020). This
is consistent with some previous studies. For example, Cui et al. found that the
accumulation of both LC3b-II and p62 was due to the impairment of autophagosome
clearance (Cui, Sun et al. 2017). González-Rodríguez et al. showed that both LC3II/LC3-I ratio and p62 were increased when autophagic flux was inhibited (GonzalezRodriguez, Mayoral et al. 2014). My results, therefore, suggested that excessive QA
only initiated the autophagy process and impaired the completion of the autophagy
process.
Furthermore, my results revealed that the mechanism of olanzapine is complex. My
previous study demonstrated both memantine and ifenprodil (NR2B receptor-specific
antagonist) could reduce QA-induced neurite lesions. Here I also found that ifenprodil
prevented QA-induced ROS, which suggests the involvement of NR2B receptors.
Olanzapine is an antipsychotic drug and D2R is the main target for olanzapine.
However, Zhang et al. also indicate that olanzapine affects the function of NMDA
receptors by preventing NMDA-NRG1 interaction (Zhang, Yu et al. 2016). In addition,
D2R is known to interact with NR2B directly (Liu, Chu et al. 2006). Therefore, how
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olanzapine affects excessive QA-induced ROS formation can be very complex and need
further research.
In summary, this study demonstrates that excessive QA causes ROS formation and
autophagy impairment in SH-SY5Y cells. Antipsychotic drug olanzapine with a low
dose reduces QA-induced ROS and promotes autophagy. Future studies are needed to
investigate how low-dose olanzapine affects the autophagy process in neuronal cells.
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Chapter Five
Identification of signalling pathways in NR2B loss of function
cells by integrated bioinformatics analysis
5.1

Abstract

N-methyl D-aspartate receptor subunit NR2B hypofunction is a pathology of
schizophrenia. The mechanism of action is still largely unknown while several
hypotheses have been made. In my study, genes differentially expressed between NR2B
loss of function and control human cells were identified and used to construct proteinprotein interaction networks showing closely related genes. Gene Ontology (GO)
enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were
used to investigate the pathways associated with the differentially expressed genes
(DEGs). In conclusion, the present study suggests that the genes associated with
neuronal differentiation, ROS, and cell cycle are significantly changed due to NR2B
loss of function (LOF). Furthermore, I report that the IGF1R-FOXO pathway is altered
due to NR2B loss of function. My findings may offer a systematic approach for a better
understanding of the neuropathology of NMDAR hypofunction relevant to
schizophrenia.
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5.2

Introduction

N-methyl D-aspartate receptors (NMDAR) are a major group of glutamate-dependent
ion channels at excitatory synapses in nerve cells. Three different subunits are found in
NMDA receptors, which are named NR1, NR2, and NR3, respectively. Among them,
four different structures are discovered in the NR2 subunit and are called NR2A, NR2B,
NR2C, and NR2D (Vyklicky, Korinek et al. 2014). A functional NMDA receptor
contains 4 subunits, while two of them are NR1 subunits and the other two subunits are
variable. It is usually called di-heteromeric NMDA receptors when the two variable
subunits are the same (For example, NR1/NR2B receptors), and tri-heteromeric NMDA
receptors when the two variable subunits are different (for example, NR1/NR2A/NR2B
receptors) (Paoletti, Bellone et al. 2013). Among them, NR2B, also known as
Glutamate [NMDA] receptor subunit epsilon-2 (GluN2B), is a di-heteromeric NMDA
receptor and is composed of two different subtypes, two NR1 subunits and two NR2B
subunits (Paoletti, Bellone et al. 2013). The extracellular part contains a ligand-binding
domain that can bind to its ligands or agonists (Paoletti and Neyton 2007). Once the
ligands are bound, NR2B can initiate its intracellular signalling pathways (Hardingham
and Bading 2003). The importance of NR2B has already been noticed decades ago.
There are two highly accepted hypotheses proposed for contributing to the
neuropathology of psychiatric disorders. One of them is the glutamate hypothesis,
which refers to the receptors of the glutamatergic system including NR2B (Olney,
Newcomer et al. 1999). NMDA receptor antagonist memantine is a medication used for
Alzheimer’s disease.
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Although previous studies have shown that NR2B plays a key role in the progress of
psychiatric disorders, its mechanism is still largely unknown. In schizophrenia patients,
memory loss and cognitive impairment are always observed together with synaptic
plasticity impairment (Crabtree and Gogos 2014). Rats with NR2B deficits show
cognitive impairment (Clayton, Mesches et al. 2002). Another study shows that NMDA
receptor antagonists deteriorate schizophrenia-like symptoms in both healthy people
and patients (Moghaddam and Javitt 2012). Mice with NMDA receptor deletion
showed schizophrenia-like symptoms (Paoletti, Bellone et al. 2013). Furthermore,
Y1472 and S1303 are important phosphorylation sites of NR2B, which are considered
potential targets for the treatment of psychiatric disorders. For example, pY1472 of
NR2B can affect NR2B surface distribution in the cell and thus affect NR2B activity
(Nakazawa, Komai et al. 2001, Roche, Standley et al. 2001). The pS1303 of NR2B is
known to interact with several G protein-coupled receptors (Qiu, Li et al. 2011)
including the dopamine D2 receptor, the most important target in schizophrenia
research (Liu, Chu et al. 2006). The antipsychotic drug olanzapine improves NMDA
receptor impairment via Fyn Y420 phosphorylation and NR2B Y1472 phosphorylation
(Zhang, Yu et al. 2016). Clozapine also has some effects but clozapine’s binding site
on NMDAR is not clear (Bjarnadottir, Misner et al. 2007, Zhang, Yu et al. 2016). In
addition to NMDA receptor-induced neuronal impairment, neurogenesis and
differentiation are also found to be associated with NMDA receptor activation (Nacher
and McEwen 2006).
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The Gene expression profiling technique has been widely used in identifying
schizophrenia-associated genes, revealing the biomarkers, and thus predicting key
pathways of the disease (Mirnics, Middleton et al. 2001). Many gene-based studies
from post-mortem brain samples have made great progress in schizophrenia and other
psychiatric disorders research. By analyzing these data, new targets and pathways have
been identified in schizophrenia and neurodegenerative diseases. This study aimed to
investigate the altered gene expression and its associated signalling pathways in
response to NR2B loss of function.
5.3
5.3.1

Materials and methods
Microarray data collection

‘ GRIN2B’, ‘neuron’, and ‘Homo sapiens’ were used as keywords to search the
microarray

expression

profile

datasets

in

the

NCBI

GEO

database

(https://www.ncbi.nlm.nih.gov/geo/). I collected the set of gene expression profiles
from the Gene Expression Omnibus database (GSE114685). Samples derived from
three NR2B loss of function (LOF) subjects and another three as controls were
examined.
5.3.2

Data retrieval and preparation

The Limma packages of R were used to identify DEGs between LOF groups and control
groups. Only raw datasets that satisfied the threshold (|FC| > 2 and P-value < 0.01) were
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considered as differentially expressed genes (DEGs). The volcano plot was plotted
using ggplot2 packages.
5.3.3

Functional enrichment analysis on KEGG and GO

To investigate the biological function of the genes, GO terms and KEGG pathway was
performed using the Database for Annotation, Visualization, and Integrated Discovery
(DAVID) (http://david.ncifcrf.gov). These analyses revealed down-regulated and upregulated genes between groups.
5.3.4

Gene interaction network analysis

The gene interaction networks were analyzed by the STRING database version 11.0
(http://string-db.org). The interaction networks of differential expression genes were
visualized by Cytoscape 3.6.0 software (http://www.cytoscape.org/). In the present
study, the top 10 genes with the highest degree values (>60) were identified as hub
genes.
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5.4
5.4.1

Results
Identification of DEGs

Fig 5.1 The flowchart of the bioinformatics analysis.
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The flow chart in the present study was shown in Fig. 5.1. I identified 1171 DEGs with
|FC| > 2 and P-value < 0.01 as the threshold. Finally, I found 819 up-regulated genes
and 352 down-regulated genes. Fig. 5.2 showed the distribution of the DEGs via the
volcano plot.

Fig 5.2 Expression profiles of mRNA measured by microarray in NR2B LOS group
and control group. The horizontal line corresponds to fold change (log10 scaled) and
the vertical line represents the P-value (−log10 scaled). Red plots indicate DEGs with
FC > 2 and blue plots indicate DEGs with FC <-2.
5.4.2

GO and KEGG pathway analysis

To investigate the roles of the DEGs, Gene Ontology Term Enrichment was used to
analyze the data in DAVID database. The top 10 terms on cellular component,
biological process, and molecular function (CC, BP, and MF) for upregulated and
downregulated genes were displayed in Fig. 5.3. In the BP group, the upregulated DEGs
were enriched in nuclear division, cell cycle, and cell transport. The downregulated
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DEGs were associated with nuclear division, cell cycle, and signal transduction.
Moreover, in the CC group, the upregulated DEGs were enriched in microtubule,
condensed chromosome kinetochore, and membrane. The downregulated DEGs were
related to cytosol, phagocytic vesicle, membrane, and axon hillock. In the MF group,
the upregulated DEGs were enriched in protein binding, microtubule binding, and
activity. The downregulated DEGs were associated with calcium ion binding, protein
serine/threonine kinase activity, and binding. In addition, KEGG pathway analysis
revealed that the upregulated DEGs were enriched in the sphingolipid signalling
pathway, focal adhesion, and dopaminergic synapse. The downregulated DEGs were
associated with pluripotency of stem cells, Influenza A, and TNF signalling pathway
(Fig. 5.4).
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Fig 5.3 GO classification of up and downregulated DEGs. The top 10 terms were listed
according to their log p values. Blue lines are biological process, green lines are cellular
component, red lines are molecular function. (A) Top 10 upregulated BP, CC, and MF
terms. (B) Top 10 downregulated BP, CC, and MF terms.
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Fig 5.4 KEGG pathway analysis of up-DEGs (A) and down-DEGs (B) pathways.
Pathways were listed according to their log p values.
5.4.3

PPI network analysis and hub genes screening

To investigate the interaction between DEGs, a protein-protein interaction network was
constructed using Cytoscape software. The network was based on expression changes
of DEGs. The top 10 DEGs with the highest degrees of change were CDK1, CCNB1,
CCNA2, ESR1, TOP2A, ASPM, KIF11, CENPE, BUB1B, and BUB1. Details for the
top 10 hub genes were listed in Supplementary Table 5.1.

Fig. 5.5 Gene interaction network of 7 key genes. Red, IGF1R-FOXO3 pathway-related
genes; Green, neuronal differentiation-related genes; Blue, ROS-autophagy related
genes.
To further refine the key genes and pathways, I then studied the GO terms and KEGG
pathways for the top 5 hub genes. I found cell cycle and FOXO signalling pathways
were most significantly changed. Moreover, cellular response to amyloid-beta, insulin
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receptor signalling pathway, and antral ovarian follicle growth was found as the most
significant BP terms. Notably, from the FOXO3 signalling pathway suggested by the
KEGG analysis, I found insulin receptor-mediated FOXO signalling pathway was
significantly changed. To further explore the relationship between these genes, I
constructed a PPI network with hub gene ESR1 and its related IGF1-FOXO3 pathway.
The new PPI network was shown in Fig. 5.5.
5.5

Discussion

The pathological mechanism of the NR2B hypofunction in psychiatric disorders, such
as schizophrenia, is still largely unknown. Previous studies focused on the ligandreceptor binding, where the glutamate hypofunction and dopamine hyperfunction
hypotheses were highly accepted in the development of schizophrenia. In this study, I
analyzed the DEGs in the NR2B LOF cells. I also performed GO and KEGG analyses
to determine the functions and signalling pathways of the DEGs.
The GO enrichment analysis showed that the BP terms for most upregulated genes were
most relevant to the cell cycle and proliferation, such as mitotic nuclear division and
cell division. For downregulated genes, many were associated with neuronal
differentiation, such as axon hillock and synaptic vesicle in CC terms and calcium ion
binding in MF terms. Furthermore, the KEGG analysis revealed that both the Influenza
A and TNF signalling pathways were significantly changed in the downregulated genes;
both of them were associated with cell stress and ROS. In addition, by constructing the
PPI network, I identified 10 hub genes, among which the insulin receptor signalling
pathway was significantly changed. Therefore, my results suggest that neuronal
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differentiation, ROS and autophagy, insulin-receptor signalling, and cell cycle are all
important factors in response to the NR2B hypofunction.
First of all, there were several upregulated GO terms associated with cell cycle
regulation. Furthermore, the PPI network analysis showed that most of the upregulated
hub genes were also related to the cell cycle. For example, cyclin-dependent kinase 1
(CDK1), cyclin B1 (CCNB1), and centromere protein E (CENPE) can regulate the G2
phase of the cell cycle. During the development of the CNS, both neuronal proliferation
and differentiation are important for the neurogenesis process. However, neuronal
differentiation is always initiated when the neuron cell cycle is stopped. Fan and
colleagues measured the cell proliferation rate in schizophrenia-derived cells and found
an increased proliferation rate accompanied by a high expression level of cyclin D1 and
A2 (Fan, Abrahamsen et al. 2012). There are several cell cycle-related genes found to
be upregulated in schizophrenia patients in the work of Okazaki et al., suggesting that
these genes can be used as a biomarker for schizophrenia (Okazaki, Boku et al. 2016).
My study also found that several cell cycle-related genes were upregulated in NR2B
LOF cells, which might be an important feature in schizophrenia.
Three downregulated GO terms were found to be associated with neuronal
differentiation in this work, which indicated the inhibition of neuronal differentiation
after NR2B LOF. Among the top 10 hub genes, ESR1 was closely related to neuronal
differentiation. The GO enrichment analysis of ESR1 showed that the cellular response
to amyloid-beta and insulin receptor signalling pathway were most significantly
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changed, suggesting the involvement of 4 important genes (MAPK1, FOXO3, PIK3CA,
and IGF1R) (green genes in Fig. 5.5) in regulating neuronal differentiation. Zhang and
colleagues revealed that insulin-like growth factor-1 (IGF-1) can promote neuronal
differentiation via the PI3K/Akt pathway (Zhang, Zhang et al. 2014). Meanwhile,
previous studies showed IGF-1 to be important in regulating axon formation and
regeneration (Sosa, Dupraz et al. 2006, Dupraz, Grassi et al. 2013). FOXO3 is known
to regulate neuroblastoma differentiation in SH-SY5Y cells via the PI3K/Akt pathway
(Mei, Wang et al. 2012). Notably, IGF-1 and FOXO3 were also found to be aberrant in
obesity-associated dementia, and IGF-1 resistance was considered a contributor to the
pathogenesis of Alzheimer’s disease (Moll and Schubert 2012). MAPK3/1 (also known
as ERK1/2) is another important pathway that regulates neuron differentiation (Li,
Theus et al. 2006, Qiao, Paul et al. 2012) along with PI3K/Akt, and via both pathways,
estrogen receptor 1 (ESR1, also known as ERα) is known to regulate neuronal
differentiation (Merot, Ferriere et al. 2005). In this work, significant changes were
observed in all these genes and pathways due to NR2B LOF, which further confirmed
that the NR2B hypofunction significantly affects neuronal differentiation. It is worth
noting that ESR1 was significantly increased in the NR2B LOF group. Zhang and
colleagues showed that the ESR1 knockout would further deteriorate the cognitive
impairment induced by NR2B inhibition (Zhang, Liu et al. 2020). Therefore, I suggest
that the increase of ESR1 is in compensation for the NR2B inhibition. Moreover, the
ESR1 and NR1 subunits of the NMDA receptors were found to be colocalized in dorsal
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horn neurons (Tang, Ji et al. 2008), which suggests that ESR1 can be directly affected
by NR2B LOF, while the PI3K/Akt and ERK1/2 pathways are affected via ESR1.
The KEGG pathway analysis showed that the Influenza A and TNF signalling
pathways were significantly changed. As a result, ESR1, PIK3CA, FOXO3, and
PARP1 were significantly changed, which are all important genes in ROS and
autophagy regulation (blue genes in Fig. 5.5). Cook et al. reported that the knockdown
of ESR1 increases LC3b-II and decreased p62, suggesting the stimulation of autophagy
(Cook, Clarke et al. 2014). Barbati and colleagues showed ESR1 to be important for
autophagy activation and cell survival in neuroblast SH-SY5Y cells when the cells were
exposed to long-term cell stress (Barbati, Pierdominici et al. 2012). Moreover, synaptic
NMDA receptors are known to activate the PI3K/Akt pathway, protecting neurons from
damage resulting from ROS accumulation (Papadia, Soriano et al. 2008). PARP1 was
shown to activate FOXO3a followed by the initiation of autophagy (Wang, Xu et al.
2018). It is worth noting that the PI3K/Akt pathway can regulate FOXO3 and affect
ESR1 (Guo and Sonenshein 2004), and both ESR1 and PI3K are important targets of
the NR2B receptor. Therefore, I believe that these genes are directly affected by the
NR2B dysfunction.
In line with the KEGG analysis of ESR1, I further explored the FOXO pathway. I
found that 4 genes (IGF1R, PIK3CA, CHUK, and FOXO3) in the pathway provided by
the KEGG website were in the same pathway to regulate the activity of the FOXO gene
(red genes in Fig. 5.5). Previous studies indicated that the IGF1R-FOXO signalling
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pathway affects brain function. The reduction of FOXO3 was found to be associated
with the formation of obesity-induced cognitive impairment (Moll and Schubert 2012).
Furthermore, Weeks and colleagues found that antipsychotic drugs, such as olanzapine
and clozapine, increase the IGF1R-FOXO signalling pathway in C. elegans (Weeks,
Dwyer et al. 2010). In this study, I also found that the NR2B hypofunction led to a
significant change in the IGF1R-FOXO signalling pathway; thus, the dysregulation of
the IGF1R-FOXO pathway might be an important biomarker in schizophrenia research.
In summary, this work identified the key genes and pathways that were significantly
changed due to NR2B LOF. GO and KEGG analysis revealed that NR2B LOF can
significantly alter the regulation of neuronal differentiation, ROS-autophagy, and cell
cycle. I report here for the first time that the IGF1R-FOXO pathway is altered due to
NR2B loss of function, which may be part of the neuropathology of schizophrenia.
5.6
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Table 5.1 Top 10 hub genes, either up-regulated or down-regulated
Gene symbol

Protein name

Degree

logFC

P.Value

CDK1

UP/D

Cyclin-dependent kinase 1

75

0.808

0.003

UP

CCNB1

Cyclin B1

73

0.685

0.0002

Down

CCNA2

Cyclin A2

65

0.975

0.002

UP

ESR1

Estrogen Receptor 1

64

-0.403

0.003

UP

TOP2A

DNA Topoisomerase II Alpha

64

1.176

0.003

UP

ASPM

Assembly Factor For Spindle Microtubules

61

1.379

0.002

UP

KIF11

Kinesin Family Member 11 or kinesin-5

61

1.089

0.004

UP

CENPE

Centromere Protein E

61

1.167

0.006

UP

BUB1B

Mitotic Checkpoint Serine/Threonine Kinase B

60

0.776

0.004

UP

BUB1

Mitotic Checkpoint Serine/Threonine Kinase

60

1.039

<0.0001

Down
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Table 5.2 Top 5 GO and KEGG pathways for ESR1 gene

KEGG
hsa04068:FoxO signalling pathway

Count P-Value
11

7.94E-09

9

5.78E-08

hsa04014:Ras signalling pathway

12

1.11E-07

hsa05200:Pathways in cancer

14

5.81E-07

9

3.00E-06

hsa04914:Progesterone-mediated oocyte maturation

hsa05161:Hepatitis B
BP

Count P-Value

GO:0045893~positive regulation of transcription, DNA-templated

18

<0.001

GO:0045944~positive regulation of transcription from RNA polymerase II promoter

21

<0.001

GO:0000122~negative regulation of transcription from RNA polymerase II promoter

17

<0.001

GO:0000187~activation of MAPK activity

7

<0.001

GO:1904646~cellular response to beta-amyloid

2

<0.001

CC

Count P-Value

GO:0005654~nucleoplasm

30

<0.001

GO:0005634~nucleus

39

<0.001

GO:0016020~membrane

19

<0.001

GO:0005730~nucleolus

11

<0.001

GO:0005737~cytoplasm

30

0.003
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MF

Count P-Value

GO:0005515~protein binding

58

<0.001

GO:0043565~sequence-specific DNA binding

12

<0.001

GO:0005524~ATP binding

19

<0.001

GO:0003700~transcription factor activity, sequence-specific DNA binding

15

<0.001

5

<0.001

GO:0001102~RNA polymerase II activating transcription factor binding
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Chapter Six
6.1

Overall discussion and conclusions

This thesis investigated the mechanism of QA-induced neurite lesions. NMDA receptors
and ROS contributed to QA-induced impairment in neurons. Both NMDA receptor
antagonists (ifenprodil, MK-801, memantine) and the antipsychotic drug olanzapine
alleviated this impairment. This chapter gives a general discussion of key findings in my
Ph.D. thesis.
Firstly, I studied the mechanism of how QA-induced neurite lesions in neuronal cells. In
Chapter 2, I found that QA caused neurite lesions in SH-SY5Y cells via the overactivation
of NMDA receptors. A decrease in pCREB and BDNF expression revealed that QA
activated a pro-death signalling pathway initiated by extrasynaptic NMDA receptors but
not synaptic NMDA receptors. The blockade effect of memantine further confirms that
NMDA receptors are involved in QA-induced impairment. Moreover, this may explain
how memantine alleviated symptoms of Alzheimer’s. In addition to the NMDA receptor
signalling pathway, QA also induced the increase of ROS in SH-SY5Y cells. In Chapter
4, my study showed both total ROS and mitochondrial ROS are significantly increased
after 100 µM QA treatment. This concentration is consistent with the previous experiment
which could induce a pre-death signalling pathway of NMDA receptors. The addition of
NMDA receptor antagonist ifenprodil and MK-801 can reverse QA-induced ROS,
suggesting the involvement of NMDA receptors. I also found that olanzapine at a low
concentration reduced QA-induced ROS and autophagy in SH-SY5Y cells while a high
concentration of olanzapine could not prevent QA-induced impairment in cells. These
results suggested that dosage is an important factor for olanzapine treatment in neurons.
Moreover, my results indicated that memantine could not reverse QA-induced ROS, and
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this suggested an NMDA receptor-independent signalling pathway was involved in QAinduced ROS.
To further understand the relation between NR2B and D2R receptors, I investigated the
interaction between NR2B and D2R. In Chapter 3, my results revealed a direct reciprocal
interaction between D2R and NR2B at the receptor level. I found that NR2B hyperactivity
caused an upregulation of GSK-3β. On the other hand, D2R hypoactivity could directly
increase Y1472 phosphorylation and expression of NR2B, suggesting that NR2B activity
could be regulated by D2R. I found that phosphorylation of NR2B Y1472 also changed
due to the inhibition of D2R, and this suggested D2R also affected NR2B distribution in
the cell membrane. Table 6.1 summarized the main findings of the thesis.
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Table 6.1 Summary of main findings in the thesis

Parameter

Treatment

Neuronal Morphology
Cell viability in SH-SY5Y cells
Neurite length in SH-SY5Y cells
Cell viability in cortical cells
Neurite length in cortical cells
PSD95 in SH-SY5Y cells
NR2B signalling pathways
pCREB in SH-SY5Y cells
BDNF in SH-SY5Y cells
pY1472 in SH-SY5Y cells
CaMKII in SH-SY5Y cells
D2R signalling pathways
D2R in SH-SY5Y cells
Ser9 of GSK-3β in SH-SY5Y
cells
ROS
Total ROS
Mitochondria ROS
Autophagy pathways
p62
LC3 II/LC3 I

QA

QA with
memantine

QA with
ifenprodil

QA with
NR2B
siRNA

↓***
↓***
↓***
↓***
↓*

↑#
↑#
↑#

↑#
↑##
↑#

↑#
↑#

↓*
↓***

↑###
↑##

↑#
↑#

↑###
↑##

↑***
↑*

N.S.

N.S.
↑**

N.S.
N.S.

↓##

QA with low
dose
olanzapine

↑#

NR2B
plasmids
with
quinpirole

NR2B
plasmids

Reduced
D2R activity

Reduced
D2R activity
with
ifenprodil

↓*
↓***

↑**
↑**

↓*
↓***

↑**

-

-

↑*
↑***

↓*
↓*

N.S.

N.S.

N.S.

-

↑*

↓*

↑*

-

↓#

↓###
N.S.
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6.1.1

Overall discussion of the findings

In neurodegenerative diseases such as Alzheimer’s, QA is found abnormally high.
Excessive QA is known to over-stimulate NMDA receptors in the brain, causing severe
excitotoxicity. Over-stimulation of NMDA receptors, especially NR2B receptors, is
known to cause significant neurite lesions. However, the exact mechanism is still largely
unknown. This thesis focused on three major signalling pathways. The first pathway is
via NR2B-pCREB-BDNF. CREB and BDNF are important targets in NR2B mediated
pre-death signalling pathways. The second pathway is via interaction with D2R. These
two pathways are particularly relevant to many therapeutic strategies such as memantine
and quinpirole. The third pathway is via ROS-autophagy. This study showed autophagy
plays a vital role in regulating neurites when the autophagy process is dysfunctional. This
thesis provides critical information to support that over-stimulation via these three
pathways causes significant neurite lesions. However, specific targets such as olanzapine
and memantine can prevent excessive QA-induced neurite lesions.
In Chapter 2, I found that over-stimulation by QA in neuronal cells could cause neurite
impairment via the NMDA receptor-dependent signalling pathway. Notably, QA-induced
neurite lesions were dose-dependent. Hernandez-Martinez et al. reported 50 - 150 nM QA
increased neurite growth in SH-SY5Y cells. They also found that high concentration
(reach to 1 μM) reduced neurites. This is consistent with my finding that QA has a
bilateral effect on neurite growth in neurons. In neurodegenerative diseases such as
Alzheimer’s, QA is found to be abnormally high in the brain. Therefore, I studied the
effect of a high concentration of QA and found that 100 µM QA caused more neurite
impairment than 300 µM glutamate, a well-known neurotoxin that causes excitotoxicity.
These results showed excessive QA-induced severe neurite impairment.
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In Chapter 2, I further investigated the signalling pathway involved in QA-induced
neurite impairment. I found that both NMDA receptors and ROS-autophagy were affected
by QA. I studied the NMDA receptor signalling pathway in this chapter. The ROSautophagy pathway was discussed in Chapter 4. I examined the downstream proteins and
found that pCREB and BDNF had the most significant change after QA treatment.
Decreases in pCREB and BDNF are known to cause neurite impairment being important
downstream pathways of NMDA receptors (Nair and Vaidya 2006). Remarkably, QA is
the agonist of the NMDA receptor. Under normal physiological conditions, NMDA
receptors will increase pCREB and BDNF via calcium influx (Vanhoutte and Bading
2003). However, in this study, I showed that QA overactivated NMDA receptors and
decreased pCREB and BDNF. This is a typical pathological condition. In
neurodegenerative diseases, NMDA receptors are always found hyper-activated.
Meanwhile, these activated NMDA receptors decreased pCREB and BDNF instead of
increasing them. This is because the overactivation of NMDA receptors triggers a prodeath signalling pathway, especially in the extrasynaptic region. Overactivation of
extrasynaptic NMDA receptors will cause inactivation of ERK 1/2 and then inhibit the
phosphorylation of CREB in the cells, showing an opposite effect from the pathway in
physiological condition (Gladding and Raymond 2011). Previous studies indicated that
overactivation of extrasynaptic NMDA receptors first induced a short augment of CREB
phosphorylation, accompanied by a sustained CREB-dephosphorylation signal afterward
(Hardingham and Bading 2010). The data in this study also showed that a high dose of
QA significantly decreased pCREB and BDNF, suggesting an NMDA receptor-induced
pre-death pathway was involved.
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I then used NR2B receptor antagonist ifenprodil, NR2B siRNA, and memantine to block
the effect of QA. Memantine is a well-known medicine in the treatment of AD.
Memantine is a partial NMDA receptor antagonist, and this antagonism is also considered
its primary function in the treatment of AD (Parsons, Stoffler et al. 2007). Meanwhile,
previous studies have indicated that memantine blocks extrasynaptic NR2B receptors
more effectively than synaptic NMDA receptors (Xia, Chen et al. 2010). I used
memantine to block NMDA receptors and found it alleviated QA-induced neurite lesions
at the concentration of 1 µM. Moreover, NR2B receptor antagonist ifenprodil also showed
a similar effect, further confirming that NR2B receptors are overactivated by QA and
induce neurite lesions in SH-SY5Y cells. Additionally, the usage of NR2B receptor
siRNA also concluded the involvement of NR2B receptors in QA-induced neurite lesions.
In neurodegenerative diseases including AD, QA concentration is increased in the brain
(Schwarcz, Bruno et al. 2012). Overactivation of NMDA receptors is thus a possible
pathway of QA-induced neurite lesions in neurons.
In Chapter 3, I confirmed that overactivation of NR2B by using NR2B plasmids could
lead to severe neurite lesions. Its direct downstream protein CaMKII was also
significantly reduced. Notably, GSK3β was significantly affected due to NR2B
hyperactivation. GSK3β is a well-known downstream protein of D2R (Beaulieu,
Gainetdinov et al. 2009). Therefore, I hypothesized that NR2B can affect D2R in the cell
membrane. I later used D2R agonist quinpirole to reverse the effect of NR2B plasmids. I
found quinpirole successfully alleviated NR2B plasmids induced neurite lesions in SHSY5Y cells, strongly suggesting that NR2B may affect D2R directly.
I further investigated whether D2R can affect the NR2B signalling pathway. Liu et al.
have studied the long-form of D2R and found that activation of D2R in the postsynaptic
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region can inhibit NR2B induced LTP in the striatum. In their study, D2R significantly
affected pS1303 of NR2B, suggesting a high D2R-NR2B interaction on this site (Liu,
Chu et al. 2006). However, it is still unclear whether D2R inhibition could affect NR2B
and its phosphorylation sites. In Chapter 3, I found that D2R hypoactivity could directly
increase pY1472 and NR2B expression in SH-SY5Y cells. Since pY1472 is a key target
for surface distribution of NR2B receptor (Matsumura, Kunori et al. 2010), the result
suggested D2R siRNA can not only affect NR2B expression but also NR2B distribution
on the cell membrane.
Based on the above findings, I suggested that NR2B and D2R can interact with each other
in the cell membrane and used FRET to confirm this interaction. FRET is used for testing
the physical interaction of two proteins. The emission wavelength of the first protein
becomes the second protein’s excitation wavelength. The microscope receives emission
fluorescence from the second protein, although not from any excitation wavelength for
the second protein. In Chapter 3, I found that quinpirole led to a stronger FRET signal,
confirming that D2R activation could increase NR2B-D2R interaction.
In addition to the NMDA receptor signalling pathway, QA also induced the increase of
ROS in neuronal cells. In Chapter 4, results showed that both total ROS and
mitochondrial ROS are significantly increased after 100 µM QA treatment. This
concentration is consistent with the previous experiment, which could induce the prodeath signalling pathway of NMDA receptors. The NMDA receptor might thus not be the
only way to activate ROS in SH-SY5Y cells. I also found that ifenprodil prevents QAinduced ROS, suggesting the involvement of NR2B receptors. Moreover, I found that the
antipsychotic drug olanzapine at a low dose reduced QA-induced ROS in SH-SY5Y cells
while a high dose could not. This is interesting because the bilateral effect of olanzapine
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suggested that the concentration of olanzapine is a key factor in regulating ROS
production.
I also discovered that QA significantly affected autophagy in SH-SY5Y cells. This is
interesting. It is known that the activation of autophagy is considered a protective
mechanism to alleviate ROS-induced cell damage. For example, Kiffin and his colleagues
indicated that autophagy could help cells to remove oxidized proteins via the chaperonemediated autophagy (CMA) pathway (Kiffin, Christian et al. 2004). p62 is known to
deliver protein aggregates to autophagosomes and these proteins will decompose during
the autophagy process (Fan, Tang et al. 2010). However, I found that both p62 and LC3bII were increased in SH-SY5Y cells, suggesting an incomplete autophagy pathway. Under
normal physiological conditions, the completion of autophagy involves autolysosome
degradation which decomposes p62. Hence, p62 expression is always low when the
autophagy process is completed (Filomeni, De Zio et al. 2015). Results showed an
increase of p62 which suggested that it was not degraded with autolysosome. This is
possible since many compounds, including antipsychotic drugs, showed a similar effect
(Vucicevic, Misirkic-Marjanovic et al. 2014). Therefore, the autophagy process was
blocked in the final step of autolysosome degradation, leading to p62 accumulation. My
results suggested that QA also induced an incomplete process of autophagy in SH-SY5Y
cells, which might further exacerbate ROS-induced cell damage.
Previous studies have demonstrated that a high concentration of olanzapine can induce
ROS and autophagy, as well as decrease cell viability, all of which are similar to my
results (Vucicevic, Misirkic-Marjanovic et al. 2014). Ljubica Vucicevic et al. indicated
that 100 µM olanzapine induces both ROS and autophagy. The increase in ROS causes
neurite lesions and cell death, while the increase in autophagy protects cells from further
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impairment (Vucicevic, Misirkic-Marjanovic et al. 2014). Here, I showed that a low
concentration of olanzapine might have a different mechanism. 1 μM olanzapine
treatment decreased p62 but not LC3b-II in SH-SY5Y cells. It is therefore likely that lowdose olanzapine can promote the completion of the autophagy process, especially the final
step, autolysosome degradation. However, when high dose olanzapine was treated to cells,
I found that p62 is not decreased. Moreover, high-dose olanzapine also led to more ROS
and cell death in SH-SY5Y cells. This bilateral effect of olanzapine suggested that low
and high-dose olanzapine might have different mechanisms in regulating the autophagy
process.
In Chapter 5, I found that genes associated with neuronal differentiation, ROS, and cell
cycle are significantly changed due to NR2B LOF. This is consistent with the previous
findings since NR2B is a key regulator in neuronal differentiation. Here I identified that
the IGF1R-FOXO pathway might play an essential role since the genes in this pathway
are the most significantly changed due to NR2B LOF. These findings provide a better
understanding of NMDAR hypofunction and schizophrenia.
6.1.2

Proposed mechanism

First of all, I used excessive QA to cause neurite lesions. QA is a well-known NMDA
receptor agonist and causes the overactivation of NMDA receptors. Overactivation of
NMDA receptors will shut off CREB and thus lead to neuron injury and cell death
(Hardingham and Bading 2010). It is equally observed that most activated NMDA
receptors are extrasynaptic NMDA receptors (Hardingham and Bading 2010). In
pathological conditions, extrasynaptic NMDA receptors are activated (Gladding and
Raymond 2011). These receptors initiate pro-death signalling pathways and induce cell
death. For example, in AD, it is known that the NMDA receptor is overactivated (Paoletti,
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Bellone et al. 2013). Therefore, I believe that the NMDAR - CREB - BDNF pathway
could explain QA-induced neurite lesions. Additionally, ifenprodil is found to inhibit
these QA-induced neurite lesions, which suggested the involvement of NR2B receptors.
Previous studies have found that most extrasynaptic NMDA receptors are NR2B subunits,
which suggests NR2B are responsible in NMDA receptor-induced neurotoxicity.
Moreover, memantine also inhibit QA-induced neurite lesions, which suggested that
memantine can inhibit NMDA receptor-induced neurotoxicity. This is also consistent
with previous studies. For example, Xia et al. found memantine mainly inhibits the
function of extrasynaptic NMDA receptors while it has little effect on synaptic NMDA
receptors (Xia, Chen et al. 2010).
Overall, a high concentration of QA could cause neurite lesions in SH-SY5Y cells in
which NMDA receptors are involved. A decrease in CREB and BDNF expression reveals
a possible signalling pathway for QA. This may represent another aspect of the
kynurenine pathway in regulating neuronal activity. The blockade effect of ifenprodil and
memantine further confirms that NMDA receptors, especially NR2B receptors, are
important targets in neurodegenerative diseases.
D2R are important targets in schizophrenia research. Previous studies suggested that
antipsychotic drugs can alleviate the symptoms in neurodegenerative diseases such as
Alzheimer’s disease. Moreover, previous studies have shown that D2R and NR2B
receptors can affect each other. Therefore, in Chapter 3, I studied the interaction between
NR2B and D2R. I used D2R siRNA to inhibit D2R expression levels in the cell. Results
showed that D2R siRNA can increase protein expression level of NR2B and its
phosphorylation at the Y1472 site. Since phosphorylation of NR2B Y1472 leads to
surface distribution of NR2B, the result suggested D2R siRNA can not only affect NR2B
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expression but also NR2B distribution on the cell membrane. Moreover, I found that the
expression of CaMK II, a direct downstream protein of NR2B that controls calcium influx,
also increased due to inhibition of D2R inhibition. Therefore, D2R siRNA might also
increase the activity of NR2B. It is understood that hyper-activated NMDARs lead to
rapid neuronal death due to excitotoxicity. Thus, the neurite lesions caused by D2R
inhibition might be due to the hyperactivity of NR2B. On the other hand, NR2B
hyperactivity induced neurite lesions could also be inhibited by D2R agonist quinpirole.
This also proved that D2R could play an important role in hyper NR2B induced
excitotoxicity. FRET results equally confirmed that a direct D2R-NR2B interaction could
be regulated by D2R activity. Together, my results support that D2R-NR2B has direct
interaction. Therefore, in psychiatric diseases, NR2B or D2R should not be considered
separately as their interaction and balance could be more important.
In Chapter 2, I studied the QA-induced NMDA receptor dependent pathway. Activation
of extrasynaptic NMDA receptors will shut off CREB and thus lead to an opposite effect
(Hardingham and Bading 2010). This difference is not only related to whether the NMDA
receptor is overactivated but also to its position when activated. In pathological conditions,
extrasynaptic NMDA receptors are activated (Gladding and Raymond 2011). These
receptors initiate pro-death signalling pathways and induce cell death. For example, in
AD, it is known that the NMDA receptor is overactivated (Paoletti, Bellone et al. 2013).
It is equally observed that most activated NMDA receptors are extrasynaptic NMDA
receptors (Hardingham and Bading 2010). So, I believe that the NMDAR - CREB BDNF pathway could explain QA-induced neurite lesions. Additionally, memantine
mainly inhibits the function of extrasynaptic NMDA receptors while it has little effect on
synaptic NMDA receptors (Xia, Chen et al. 2010). Thus, synaptic NMDA receptors can
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still keep their function to support cell survival and neurite growth while extrasynaptic
NMDA receptors will lose function due to the effect of memantine. This is also consistent
with my results since de-phosphorylation of Y1472 is responsible for extrasynaptic
NMDA receptors. I also tried other NMDA receptor antagonists such as ifenprodil and
MK-801, and both showed similar effect to memantine. These results further confirmed
that NMDA receptors were overactivated by QA and neurite lesions could be prevented
by NMDA receptor antagonists.
Overall, a high concentration of QA could cause neurite lesions in SH-SY5Y cells in
which NMDA receptors are involved. A decrease in CREB and BDNF expression reveals
a possible signalling pathway for QA. This may represent another aspect of the
kynurenine pathway in regulating neuronal activity. The blockade effect of memantine
further confirms that NMDA receptors are important targets in neurodegenerative
diseases.
In Chapter 3, I used D2R siRNA to inhibit D2R expression levels in the cell. Results
showed that D2R siRNA can increase protein expression level of NR2B and its
phosphorylation at the Y1472 site. Since phosphorylation of NR2B Y1472 leads to
surface distribution of NR2B, the result suggested D2R siRNA can not only affect NR2B
expression but also NR2B distribution on the cell membrane. Moreover, I found that the
expression of CaMK II, a direct downstream protein of NR2B that controls calcium influx,
also increased due to inhibition of D2R inhibition. Therefore, D2R siRNA might also
increase the activity of NR2B. It is understood that hyper-activated NMDARs lead to
rapid neuronal death due to excitotoxicity. Thus, the neurite lesions caused by D2R
inhibition might be due to the hyperactivity of NR2B. On the other hand, NR2B
hyperactivity induced neurite lesions could also be inhibited by D2R agonist quinpirole.
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This also proved that D2R could play an important role in hyper NR2B induced
excitotoxicity. FRET results equally confirmed that a direct D2R-NR2B interaction could
be regulated by D2R activity. Together, my results support that D2R-NR2B has direct
interaction. Therefore, in psychiatric diseases, NR2B or D2R should not be considered
separately as their interaction and balance could be more important.
In Chapter 4, results showed both total ROS and autophagy are significantly increased
after 100 µM QA treatment. In addition, both p62 and LC3b-II were increased, suggesting
an incomplete autophagy process. The autophagy process was blocked in the final step of
autolysosome degradation, and this will lead to accumulation of p62.
Furthermore, I investigated the effect of olanzapine on QA-induced ROS. I found
olanzapine with a low dose could reduce QA-induced ROS and autophagy in SH-SY5Y
cells while a high dose olanzapine did not prevent QA-induced impairment in cells.
Moreover, when 1μM olanzapine was used, p62 expression decreased, suggesting 1μM
olanzapine can promote the completion of the autophagy process.
Overall, my PhD study investigated how an excessive QA causes neurite lesion via three
intracellular signalling pathways, namely 1) NR2B-CaMK II-BDNF, 2) NR2B-D2RGSK3β, and 3) NR2B-ROS-autophagy. Although the three pathways can independently
affect neurites, there are intrinsic connections and protein site-specific functions revealed
in my study. These crosstalks and protein site-specific functions indicate the complexity
of the cell regulatory mechanism in response to an elevated level of QA, representing
brain inflammation across many brain diseases.
First, NR2B crosstalks with BDNF in response to the QA challenges. BDNF is a key
molecule involved in the regulation of neurites (Bathina and Das 2015). BDNF alteration
is found in the aging brain (Miranda, Morici et al. 2019). Many factors can affect BDNF
151

expression. My study showed that QA-induced neurite lesions and BDNF reduction were
blocked by ifenprodil, an NR2B antagonist. It was suggested that NR2B overactivation
caused neurite lesions via CREB dephosphorylation and BDNF inhibition. The crosstalk
between NR2B and BDNF provides a possible explanation in QA-induced excitotoxicity
reported in clinical studies.
Second, NR2B crosstalks with D2R in response to QA challenges. Previous studies have
reported the co-existence of increased NR2B and decreased D2R in Alzheimer’s and
Parkinson’s diseases (Paoletti, Bellone et al. 2013, Gallo 2019). Conversely, an increased
D2R and decreased NR2B were reported in Schizophrenia (McCutcheon, Krystal et al.
2020). My research revealed an interaction between the two receptors in a single cell.
NR2B activation inhibited D2R via its 225-234 sites. Conversely, D2R activation
inhibited NR2B via its S1303 site. Revealing the crosstalk between NR2B and D2R
provides the fundamental mechanism as a possible explanation for the above clinical
findings of these two receptors.
Third, there was crosstalk between ROS and autophagy in response to QA challenges.
My study showed that excessive QA increased ROS, which triggered the activation of
autophagy. However, the autophagy triggered by QA-ROS was incomplete because my
study showed an increased p62 production. Obviously, the two systems ROS and
autophagy crosstalked with each other as ROS activated autophagy (increased LC3bII/LC3b-I ratio). The consequence would have to depend on the function of each system,
e.g., an increased p62 rather than a decreased p62 (normal function).
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Fig 6.1 The mechanism of excessive QA and NR2B overexpression induced neurite
lesions. 1. NR2B were hyperactivated by excessive QA (100 μM) or over-expressed by
the addition of NR2B plasmid in neuronal cells. 2-5 summarized the NR2B-related
signalling pathway in the thesis. 2. NR2B S1303 was phosphorylated by the addition of
NR2B plasmid, revealing the interaction between NR2B and D2R. 3. CaMK II was highly
expressed while NR2B plasmid and D2R siRNA were added. Since CaMK II is a direct
downstream protein of the NR2B receptor, this result suggested a potential interaction
between NR2B and D2R. 4. The phosphorylation of CREB decreased when excessive
QA was added. This can be reversed by adding NR2B antagonists MK-801, ifenprodil,
and memantine. Moreover, QA-induced CREB dephosphorylation can also be reversed
by the addition of NR2B siRNA. 5. The expression of BDNF was reduced due to
excessive QA in neuronal cells. Similar to pCREB, this can also be reversed by both
NR2B antagonists and NR2B siRNA. 6. D2R expression was downregulated by the
addition of D2R siRNA. This is used to investigate the relation between NR2B and D2R.
7. GSK-3β expression was increased when D2R siRNA and NR2B plasmid were
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transfected. This result is similar to CaMK II, suggesting a direct interaction between
NR2B and D2R. 8. A summary of morphology change. Excessive QA, NR2B plasmid
transfection, and D2R siRNA transfection induced neurite lesions in neuronal cells. 9-12
summarized QA-induced ROS and autophagy change. 9. Intracellular ROS can be
activated by adding 100 μM QA. This can be reversed by NR2B antagonists MK-801 or
ifenprodil, but not memantine. Additionally, the antipsychotic drug olanzapine showed a
bilateral effect on ROS. A low concentration of olanzapine (1 μM) reduced ROS but a
high concentration of olanzapine (50 μM) induced more ROS. 10. LC3b-II was elevated
due to excessive QA, and this suggested an increase in autophagy in the cell. 11. p62 was
increased when 100 μM QA was added. Since LC3b-II was increased in QA treatment,
the elevation of p62 suggested an impaired autophagy process in the cell. Results showed
1 μM olanzapine decreased p62 but not LC3b-II, suggesting that a low concentration of
olanzapine improved the completion of autophagy. However, a high concentration of
olanzapine (50 μM) increased p62 but not decreased p62, implying that a high
concentration of olanzapine led to more impairment in the autophagy process. 12. The
autophagy process was damaged by the addition of QA, but this could be restored by 1
μM olanzapine. Meanwhile, 50 μM olanzapine could not improve the completion of the
autophagy process.
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6.2

Recommendations for future research

According to the findings of current studies, recommendations for future research are
made as follows:
1. My results demonstrated QA caused the decrease of pCREB and BDNF in SH-SY5Y
cells. QA can thus be helpful in the treatment of neurodegenerative diseases. However,
experiments in animal models and human subjects need to be done to confirm and
establish this QA-induced neuronal impairment.
2. In Chapter 3, I confirmed that hyper-activation of NMDA receptors and D2R
hypoactivity could affect each other’s signalling pathways. However, more
experiments need to be done to investigate the effect of NMDA receptor hypoactivity
and D2R’s hyperactivity in neurons. Such research can be conclusive on the reciprocal
regulation of NMDA and D2R receptors.
3. In Chapter 4, I found that 1 μM olanzapine could alleviate QA-induced ROS and
promote autophagy completion. A previous study showed that 100 μM olanzapine
caused serious ROS to the cells, suggesting that 1 μM and 100 μM olanzapine affect
ROS and autophagy via different signalling pathways. The exact mechanism of how
1 μM olanzapine alleviates QA-induced ROS needs to be further investigated.
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6.3

Conclusion

This thesis investigated QA-induced neurite lesions. First, I studied how a high
concentration of QA could cause neurite lesions in SH-SY5Y cells in which NMDA
receptors are involved. A decrease in CREB and BDNF expression levels reveals a
possible signalling pathway for QA. This may represent another aspect of the kynurenine
pathway in regulating neuronal activity. The blockade effect of memantine confirms that
NMDA receptors are essential targets in neurodegenerative diseases. I investigated the
interaction between D2R and NR2B and found that NR2B hyperactivity caused an
upregulation of GSK-3β, an occurrence when D2R is inhibited. On the other hand, D2R
hypoactivity could directly increase Y1472 phosphorylation and expression of NR2B,
suggesting that D2R can regulate NR2B activity. Moreover, I found that phosphorylation
of NR2B Y1472 also changed due to the inhibition of D2R, indicating that D2R also
affected NR2B distribution in the cell membrane. I thereafter found that olanzapine at a
low concentration can reduce QA-induced ROS and autophagy in SH-SY5Y cells. In
contrast, a high concentration of olanzapine could not prevent QA-induced impairment
in cells. I believe that at least part of the autophagy induced by olanzapine is initiated
because of ROS increase. My results thus revealed that the mechanism of olanzapine is
complicated and ROS-autophagy might not be the only factor that should be considered.
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